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ABSTRACT

REGULATION OF EFFECTIVE B CELL RESPONSES TO CHRONIC
INFECTION
Ryan P. Staupe
E. John Wherry

Chronic viral infections disrupt B cell responses leading to impaired affinity
maturation and delayed control of viremia. Previous studies have identified early
pre-germinal center (GC) B cell attrition but the impact of chronic infections on B
cell fate decisions in GCs remains poorly understood. To address this question,
we used single-cell transcriptional profiling of virus-specific GC B cells during
chronic viral infection to test the hypothesis that chronic viral infection disrupted
GC B cell fate decisions leading to suboptimal humoral immunity. These studies
revealed a critical GC checkpoint disrupted by chronic infection specifically at the
point of dark zone re-entry. During chronic viral infection, virus-specific GC B
cells were shunted towards terminal plasma cell (PC) or memory B cell (MB)
fates at the expense of continued participation in the GC. Early GC exit was
associated with decreased B cell mutational burden and antibody quality.
Mechanistically, persisting antigen and inflammation independently drove facets
of dysregulation, with a key role for inflammation in directing premature terminal
differentiation. Thus, these studies define GC defects during chronic viral
iv

infection and identify a critical GC checkpoint that is short-circuited, preventing
optimal maturation of humoral immunity.
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CHAPTER 1: Introduction
1.1 Chronic viral infections: a unique challenge for humoral
immunity
Chronic viral infections are a ubiquitous part of human life. It is estimated
that each of the 7.5 billion people on our planet is infected with 8-10 chronic viral
infections (Virgin et al., 2009). While most of these infections cause little to no
clinical disease, some, like human immunodeficiency virus (HIV) and hepatitis C
virus (HCV), cause significant morbidity and mortality worldwide (WHO, 2019).
Evasion and subversion of the adaptive immune system is fundamental to the
establishment of chronicity during an infection. Chronic viral infections, which are
defined by the presence of chronic antigen and persistent inflammation,
represent a particular challenge for the adaptive immune system which must
balance pathogen control with host immunopathology in establishing
homeostasis (Virgin et al., 2009). This balance between viral clearance and
immunopathology results in adaptive immune responses that are altered—and
typically less functional—than are adaptive responses to acute infection.
The study of adaptive immune dysregulation in chronic viral infections has
largely focused on dysregulation of the CD8 T cell response. The phenotype of
CD8 T cells exposed to chronic viral infection and chronic antigen is termed
exhaustion and has been the basis for revolutionary basic and translational
immunology. Work on CD8 T cells in chronic viral infections and chronic cancer
1

antigen exposure has defined key mechanisms of CD8 T cell dysfunction at the
protein, transcriptional, and epigenetic levels. The discoveries in this field have
now resulted in the current successes of cancer immunotherapy with tremendous
potential for continued basic scientific knowledge and clinical impact.
Humoral defects during chronic infection are also well described, but much
less is known about the mechanisms by which chronic viral infections impact the
B cell response. Hypergammaglobulinemia has long been noted as a hallmark of
chronic viral infections such as human immunodeficiency virus (HIV) (Lane et al.,
1983; Milito et al., 2004; Moir and Fauci, 2017), hepatitis C virus (HCV) (Bjøro et
al., 1994; Cashman et al., 2014; Racanelli et al., 2006), and during infection with
the chronic strain of the lymphocytic choriomeningitis virus (LCMV) in mice
(Hunziker et al., 2003; Oldstone and Dixon, 1969). However, despite increased
total antibody titers, the antibodies made during chronic viral infections are poor
quality, displaying lower affinity maturation compared to acutely resolved
infection and delayed development of virus-neutralizing function (Battegay et al.,
1993; Gray et al., 2007; Logvinoff et al., 2004). In addition, vaccine-induced
antibody responses are worse in individuals with pre-existing chronic viral
infections compared to healthy control subjects (McKittrick et al., 2013; Shive et
al., 2018; Wiedmann et al., 2000). Together, these observations suggest that
chronic viral infection impairs B cell differentiation and fate decisions, leading to
dysregulated humoral immunity. Understanding how chronic viral infections alter
the normal humoral immune response can therefore (i) define targets to
2

modulate defective humoral immunity and (ii) give mechanistic insight into the
signals that govern the B cell response.

1.2 Humoral immune responses to acute infection and
immunization
The idea that chronic viral infection leads to dysregulated humoral
immunity is based on comparisons made to the canonical, effective humoral
immune response to acute infection and immunization. Effective humoral
immunity is the establishment of antibodies and B cell memory that both control
ongoing infection and, as is the goal in vaccination, prevent establishment of
infection upon re-exposure to the pathogen (Cyster and Allen, 2019; Plotkin,
2008). The humoral immune response is initially defined by the induction of lowaffinity antibodies (MacLennan et al., 2003) that bind their target specifically and
well, and is eventually defined by the generation of plasma cells that secrete
matured antibody for years as well as the generation of B cell memory (Slifka et
al., 1998). Tight regulation of B cell differentiation into these tasks is critical for
achieving effective and long-lasting humoral immunity. Failure to properly
regulate humoral immune responses to stimuli can lead to vaccine failure or loss
of viral control (Barnett et al., 2016; Chen et al., 2018; Chou et al., 2016; Haynes
et al., 2012; Szczawinska-Poplonyk et al., 2015). This section will discuss the
initiation of the B cell response to acute infection or immunization as well as our
3

current understanding of the signals that govern B cell differentiation and
antibody formation.

1.2.1 Initiation of the B cell response
B cell differentiation begins in the bone marrow, where cells recombine
their VDJ gene segments to arrive at a novel B cell receptor (BCR) arrangement
(Hardy and Hayakawa, 2001). The resulting naïve B cells—which express a
functional, rearranged antigen receptor—then traffic to secondary lymphoid
organs (SLO) such as the spleen and lymph nodes (Junt et al., 2008; Pereira et
al., 2010). The majority of naïve B cells in SLO reside within the B cell follicles,
where they await activation and the signals to undergo competitive testing and
mutation of the BCR to produce high quality antibody in a process known as
affinity maturation (Cyster and Allen, 2019). However, not all effective humoral
immunity occurs as a result of affinity maturation. Instead, the first humoral
response occurs as a result of a second population of naïve B cells in the spleen,
termed marginal zone (MZ) B cells. MZ B cells are an innate-like population that
express high levels of IgM and CD21, have lowered activation thresholds, and
represent the first line of defense against microbial infection (Pillai et al., 2005).
MZ B cells are strategically positioned around the red pulp of the spleen and
represent a major source of IgM in the nascent antibody response. MZ B cells
therefore play a critical role in bridging the gap between the early antibody
response and the activation of follicular (Fo) B cells to produce high affinity
antibodies.
4

In contrast to their non-circulating MZ cousins, most B cells are Fo B cells
and express high levels of IgD, CD23, and CXCR5 (Batista and Harwood, 2009).
Naïve Fo B cells maintain the ability to circulate through the body’s SLOs looking
for antigen, but as their name indicates, Fo B cells can organize into microanatomical structures known as B cell follicles. The follicular structure is formed
in response to stromal cell secretion of the chemokine CXCL13, which is the
ligand for the Fo B cell chemokine receptor CXCR5 (Pereira et al., 2010). Proper
organization of naïve B cells with SLOs is critical for efficient encounter of B cells
with antigen and proper induction of humoral immunity (Allen et al., 2004; Ansel
et al., 2000). The remainder of this thesis will therefore focus on the follicular B
cell, and ‘B cell’ hereafter will refer to these follicular populations.
Induction of the Fo B cell response begins with the flow of foreign antigen
into SLO (Batista and Harwood, 2009). Naïve B cell engagement of antigen
through the rearranged BCR initiates a complex series of processes that
ultimately define the fate of each B cell. Upon cognate antigen encounter, naïve
B cells proliferate, capture the antigen, and process it for display on major
histocompatibility complex class II (MHCII) (Batista and Neuberger, 2000; Kwak
et al., 2019) Additionally, recently activated B cells upregulate costimulatory
receptors (CD80 and CD86), cell adhesion molecules (ICAM1), and chemokine
receptors (CCR7) (Cyster and Allen, 2019). Increased expression of CCR7
allows for B cell migration towards the border with the T cell zone and enhances
interaction with CD4+ T cells (Reif et al., 2002). While B cell differentiation can
happen in a T cell-independent manner (Allman et al., 2019), effective antibody
5

responses to viral infection or immunization are generally T cell-dependent
(Crotty, 2019).
Interaction with T cells at the T:B border is the first differentiation
checkpoint that B cells face. At this checkpoint, B cells enter either the
extrafollicular response or the intrafollicular response, where affinity maturation
occurs. In extra follicular responses, naive B cells undergo little BCR mutation
and instead directly transform into plasma cells (PCs) that secrete antibody
(MacLennan et al., 2003). In this path, speed and quantity is prioritized over
antibody quality as extrafollicular responses are responsible for fast production of
antibody which is not class switched (i.e. mostly IgM) and of low affinity (Kwak et
al., 2019; Takahashi et al., 1998). However, the majority of B cell biology that is
important for control of chronic infection and for the establishment of high quality,
long-lived humoral immunity requires affinity maturation during the intrafollicular
response. The intrafollicular process of affinity maturation occurs in a highly
specialized and coordinated micro-anatomical structure known as the germinal
center (GC) (Berek et al., 1991; Jacob et al., 1991). The exact signals regulating
this checkpoint are currently unclear, but commitment to the GC pathway is
known to require prolonged and sustained interaction with antigen-specific CD4 T
cells at the T:B border and subsequent expression of the GC master
transcriptional regulator Bcl6 (Kerfoot et al., 2011; Kitano et al., 2011).
Expression of Bcl6 leads to downregulation of CCR7 and upregulation of S1PR2
on recently activated B cells and therefore allows B cells (in partnership with the
6

responding T cells) to progress deeper into the follicle and to establish a nascent
GC (Haynes et al., 2007; Shaffer et al., 2000).

1.2.2 Establishment of the germinal center response
The GC response to immunization or infection evolves over time and
typically begins during the first 7-10 days of an immune response. In addition to
GC B cell precursors and T cells (now termed T follicular helper cells or Tfh), The
GC contains specialized populations of stromal cells that become activated and
begin to proliferate. These stromal cells include the CXCL13-expressing follicular
dendritic cells (FDC) and the CXCL12-expressing reticular cells (CRC) (Cyster et
al., 2000; Rodda et al., 2015, 2018). Together, expansion of the B cells, Tfh, and
stromal cells leads to physical displacement of naïve B cells, to the formation of
the follicular mantle zone, and to the physical establishment of the GC. Beyond
their role in recruiting GC B cells and Tfh via CXCL13 expression, FDC have high
expression of complement receptor I (CD35) and therefore serve as the major
antigen depot for the GC response (Heesters et al., 2014, 2013). Chemokine
expression from the two stromal cell populations is critical for the polarization of
the GC into a T cell-, FDC-, Tfh-, and antigen-rich light zone (LZ) and a CRCrich, CXCL12-rich, T cell-poor dark zone (DZ) (Allen et al., 2004; Wang et al.,
2011) GCs are not considered fully matured until this polarization of the GC is
established.

7

1.2.3 Germinal center response
Mature GCs are the primary location of antibody affinity maturation, a
cyclic process by which B cells mutate their immunoglobulin genes, compete for
antigen and Tfh cell help, and undergo clonal expansion following positive
selection (Mesin et al., 2016). Affinity maturation occurs in two distinct steps
which are uniquely partitioned between the LZ and the DZ (Victora et al., 2010,
2012). Within the LZ, GC B cells undergo positive selection wherein they capture
antigen from FDCs, process and display it on MHCII (pMHCII), and present it to
Tfh (Schwickert et al., 2011; Victora et al., 2010) . Productive pMHCII:TCR
interactions between B cells and Tfh induce expression of the pro-survival
cytokines IL-4 and IL-21 which are sensed by their cognate receptors on GC B
cells (Chevrier et al., 2017; Reinhardt et al., 2009; Weinstein et al., 2016; Yusuf
et al., 2010; Zotos et al., 2010). Survival signaling through these cytokine
pathways is vital for GC B cells; GC B cells are intrinsically pro-apoptotic, and
cells that don’t receive pro-survival cytokines will apoptose (Mayer et al., 2017).
In addition to cytokine-derived survival signals, Tfh are the primary source of
CD40 signals to GC B cells (Foy* et al., 1996; Foy et al., 1994). CD40 signals
from Tfh cells are essential in the GC reaction and (Kawabe et al., 1994) lead the
GC B cell to upregulate c-Myc and the MTORC1 signaling pathway, thereby
allowing migration to the DZ and entry into cell cycle for division and
accompanying mutation (Dominguez-Sola et al., 2012; Ersching et al., 2017; Luo
et al., 2018).
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Within the DZ, GC B cells undergo somatic hypermutation wherein in they
mutate their immunoglobulin genes, re-express BCR, and—through mechanisms
not yet understood—test for productive BCR signaling before returning to the LZ
for further positive selection (Mcheyzer-Williams et al., 2015; Mesin et al., 2016;
Stewart et al., 2018; Victora et al., 2010). Mutation of immunoglobulin genes is
accomplished by upregulation of AID, a cytosine deaminase that binds to
variable regions of the immunoglobulin genes and deaminates cytosines
(Muramatsu et al., 2000, 2002; Wang et al., 2017). Repair of these DNA lesions
by cellular DNA repair machinery (mismatch repair and base excision repair),
results in the introduction of a DNA base somatic mutation (Odegard and Schatz,
2006). It is estimated that GC B cells make 1 somatic mutation per 103 bases
during each round of cell division (Kleinstein et al., 2003). Mutations can result in
changes to the protein sequence of the BCR (replacement mutations) or no
change BCR protein sequence (silent mutations). However, not all mutations
made by AID are beneficial. Mutations can result in productive BCRs that are
able to signal or non-productive BCRs that cannot (Mayer et al., 2017). Although
not yet fully understood, testing BCR signaling productivity is a key checkpoint
regulating GC B cell DZ exit and LZ reentry, and GC B cells with non-productive
BCRs ultimately undergo apoptosis (Stewart et al., 2018).
Affinity maturation is ultimately achieved by linking cell division within the
DZ to the LZ process of intra- and inter-clonal competition for antigen and Tfh
help. Competition between GC B cells is achieved by a compounding process.
First, the amount of antigen captured by GC B cells from FDC is directly
9

proportional to the affinity of the BCR (i.e. higher affinity BCR captures more
antigen) (Gitlin et al., 2014). Second, GC B cells that have captured more antigen
then process and present more pMHCII to Tfh, thereby inducing stronger help
signals (i.e more CD40 signals) (Gitlin et al., 2014; Shulman et al., 2013; Victora
et al., 2010). Stronger help signals from Tfh cause higher affinity GC B cells to
undergo more cell divisions within the DZ in a shorter period of time, leading to
an accumulation of more mutations than lower affinity GC B cells (Gitlin et al.,
2014, 2015). However, how antigen capture and Tfh cell help in the LZ
molecularly translate into DZ reentry and increased GC B cell divisions is still
only partially understood.
The current model for how positive selection and DZ reentry are linked
has recently been summarized by Shlomchik et. al (Shlomchik et al., 2019). They
propose that BCR signaling by GC B cells leads to the phosphorylation and
inactivation of the transcription factor FOXO1 through the P13K-Akt pathway
(Luo et al., 2018), leading to loss of CXCR4 expression and retention of GC B
cells within the LZ (Dominguez-Sola et al., 2015; Inoue et al., 2017; Sander et al.,
2015). Antigen capture and presentation followed by GC B cell interaction with
Tfh leads to CD40 stimulation. Unlike in naive B cells, where NFkB is
downstream of BCR signaling, in the GC B cells, NfKB becomes downstream of
CD40 ligation (Luo et al., 2018). The CD40L-induced NFkB expression leads to
transcription of c-Myc and entry into cell cycle (Ersching et al., 2017; Luo et al.,
2018). The degree of c-Myc expression has been observed to tightly correlate
with cell proliferation; cells with more c-Myc are able to undergo more cell
10

divisions suggesting that c-Myc may act as a cell division timer within GC B cells
(Calado et al., 2012; Dominguez-Sola et al., 2012; Finkin et al., 2019).
Importantly, GC B cells require both a BCR signal and a CD40 signal to undergo
positive selection (Luo et al., 2018). CD40 induced c-Myc expression is directly
repressed by the transcription factor FOXO1 but in the presence of BCR signals
FOXO1 is inactivated allowing c-Myc expression (Luo et al., 2018; Wilhelm et al.,
2016). Combined CD40 signals and BCR also induce activation of the MTORC1
pathway, as evidenced by increased expression of phospho-S6 and the
accumulation of biomass following positive selection (Ersching et al., 2017). In
this way, increased Tfh help is permitted along with BCR signaling to promote
increased c-Myc expression in higher affinity GC B cells, allowing them to
undergo more cell divisions in the DZ and leading to increased accumulation of
somatic mutations in their immunoglobulin genes.
One aspect of GC B cell fate missing from this iterative model is that GC B
cells can also differentiate into PC or MB from directly within the GC (Cyster and
Allen, 2019; Kurosaki et al., 2015; Mesin et al., 2016; Nutt et al., 2015; De Silva
and Klein, 2015). The decision to leave the GC as a MB or PC or to continue
participating in the GC occurs in the LZ and is the second major differentiation
checkpoint that B cells face during a humoral immune response (Ise et al., 2018;
Kräutler et al., 2017; Laidlaw et al., 2017; Suan et al., 2017a). Exiting the GC
response and undergoing differentiation prevents further participation in affinity
maturation and suggests tight regulation of this cellular fate decision. Exiting the
GC reaction early as a memory B cell is likely beneficial as this would maintain a
11

relatively unmutated pool of antigen-specific MB that could mount a more diverse
response to secondary challenge. Exiting the GC reaction as a PC is a more
complicated decision. PC differentiation occurs in two distinct waves, one early
after B cell encounter with a T cell at the T:B border and one much later, after the
establishment of the GC (Shlomchik and Weisel, 2012; Weisel et al., 2016).
These two waves of PC differentiation have different BCR affinities, with the
earlier wave having lower affinity than the later one (MacLennan et al., 2003;
Takahashi et al., 1998; Weisel et al., 2016). These two observations, that postGC MB are generally lower affinity and post-GC PC are generally higher affinity,
suggests a link between affinity maturation of GC B cells and differentiation
decisions within the GC.
The link between BCR affinity and GC B cell differentiation into PC or MB
has been solidified in recent years due to the development of fate-tracking tools
and identification of PC and MB precursor populations. Phan et. al. showed,
using a PC fate tracking system (Blimp1-GFP) combined with BCR knock-in
mice, that high affinity B cells are preferentially recruited into the PC pool (Phan
et al., 2006). How high BCR affinity translates molecularly into PC differentiation
is just beginning to be understood. One factor that influences GC B cell
differentiation into PC is the transcription factor IRF4 (Klein et al., 2006; Ochiai et
al., 2013; Sciammas et al., 2006; Xu et al., 2015). IRF4 is induced downstream of
the BCR in a dose dependent way, with higher stimulation leading to more IRF4
(Ochiai et al., 2013). IRF4 at low intracellular concentrations is able to bind to
and induce transcription and expression of Bcl6 and AID (Ochiai et al., 2013).
12

However, IRF4 at high intracellular concentrations is able to bind to and induce
transcription of the PC master transcriptional regulator Blimp1 leading to
repression of Bcl6 and PC differentiation (Ochiai et al., 2013). In this way, strong
signals through the BCR can lead to PC differentiation. More recently, GC B cell
commitment to the PC fate has also been shown to require CD40 signals from
Tfh help in addition to signals from antigen/BCR alone (Luo et al., 2018).
In contrast to PC, MB originate from low affinity GC B cells. Several
groups have recently described MB precursors in the GC B cell population
(Laidlaw et al., 2017; Suan et al., 2017a); however, a consensus set of markers
defining this population has yet to be proposed. One shared feature amongst the
identified precursor populations is the upregulation of chemokine receptors
consistent with GC egress and low BCR affinity (Laidlaw et al., 2017; Suan et al.,
2017a). GC B cell differentiation into MB is associated with expression of the
transcriptional repressor Bach2 (Shinnakasu et al., 2016). Expression of Bach2
in GC B cells is inversely correlated with the strength of Tfh signaling
(Shinnakasu et al., 2016). Bach2 expression levels provide a potential link
between BCR affinity, Tfh cell help, and MB differentiation and suggest a model
where low strength BCR signals and T cell help promote MB differentiation.
The necessity for Tfh signals in GC B cell positive selection and MB and
PC differentiation suggests a “Goldilocks” model for GC B cell differentiation that
is dependent on BCR affinity/signal strength (Ise and Kurosaki, 2019). GC B cells
with high affinity BCRs undergo selection into the PC compartment whereas GC
B cells will low affinity BCRs undergo differentiation into MB. GC B cells with
13

moderate BCR affinity undergo positive selection and DZ reentry for further
rounds of affinity maturation. How the threshold is set for what signals are too
high or too low is currently unclear and whether/how these thresholds change
over the course of an immune response will require further study.
The crux of all B cell fate decisions, before compounding by differences in
Tfh help and division potential, is the rearranged and subsequently somatically
hypermutated BCR. The BCR has two primary functions, as both a signaling
molecule and as an endocytic receptor (Kwak et al., 2019; Shlomchik et al.,
2019). It is likely that both the endocytic and signaling properties of the BCR are
important in regulating GC B cell fate decisions, because GC B cell positive
selection and differentiation decisions involve both transcriptional changes and
presentation of antigen. However, despite the central role of BCR and its binding
of antigen, it is unclear how antigen availability impacts the competitive GC
process. Indeed, most studies investigating regulation of GC B cell responses
have focused on studies of immunization (Suan et al., 2015, 2017b). In contrast
to immunization, where antigen is introduced as a bolus and levels of antigen
decay over time, antigen during acute infection logarithmically increases over
time (Virgin et al., 2009). How increasing levels of antigen impact the BCRaffinity based model of GC B cell differentiation and selection is unclear. Immune
responses to chronic infection are yet another case, where antigen persists even
longer than in acute infection and far longer than in the case of traditional
immunization (Virgin et al., 2009). The relative role of prolonged antigen on B cell
fate decisions is a major topic of this thesis. However, abundant and prolonged
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antigen is not the only feature of chronic infection, and chronic inflammation likely
also plays a role in changing humoral immunity (Virgin et al., 2009). The next
sections of the introduction will therefore discuss what is known about the effects
of chronic infection on the humoral immune response and describe the mouse
model used to interrogate chronic infection more broadly.

1.3 Humoral Immunity to chronic viral infections
Effective humoral immune responses to infection and immunization are
defined by antibodies that bind pathogens and function to both prevent and, to a
lesser extent, control infection (Cyster and Allen, 2019; Dörner and Radbruch,
2007; Plotkin, 2008). Optimal antibody function requires that the antibodies have
high affinity for their pathogenic target. In contrast to humoral immune responses
to acute viral infection, immune responses to chronic infection are often
dysfunctional, characterized by increased antibody production and delayed
development of virus-neutralizing function (Battegay et al., 1993; Bjøro et al.,
1994; Cashman et al., 2014; Eschli et al., 2007; Gray et al., 2007; Hunziker et al.,
2003; Lane et al., 1983; Logvinoff et al., 2004; Milito et al., 2004; Moir and Fauci,
2017; Oldstone and Dixon, 1969; Racanelli et al., 2006). How chronic viral
infections dysregulate and evade antibody-mediated immunity is currently
unclear. Limiting access to neutralizing epitopes (Klein and Bjorkman, 2010; Moir
and Fauci, 2017; Sommerstein et al., 2015), high viral mutation rates (Bonsignori
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et al., 2017), establishment of a latent reservoir (Barton et al., 2011), and direct
infection of B cells (Barton et al., 2011) are just some of the immune evasion
strategies used by chronic viral infections to blunt anti-viral antibody responses
(Virgin et al., 2009).
Although, dysregulated humoral immunity has long been appreciated
during chronic viral infections, our understanding of the key steps in B cell
differentiation and underlying mechanisms of the dysregulation remains limited.
Recent studies have shown a role for type I interferon in driving B cell
differentiation away from the GC fate resulting in the acute depletion of B cells
during chronic viral infection before GC B cell differentiation can be established
(Fallet et al., 2016; Moseman et al., 2016; Sammicheli et al., 2016). Moreover,
chronic viral infections in mice and humans can result in lymphoid tissue
disruption and/or fibrosis (Mueller et al., 2007; Schacker et al., 2006; Wilson et
al., 2013a), perhaps impacting B cell responses. However, despite these
challenges, GC still form during chronic infection (Barnett et al., 2016; Clingan
and Matloubian, 2013; Daugan et al., 2016; Fukazawa et al., 2015), and
antibodies have been shown to diversify over time during chronic HIV and HCV
infections (Doria-Rose et al., 2014; Kinchen et al., 2018; Wu et al., 2015),
suggesting GC activity. Moreover, despite generally smaller GCs during chronic
infection, affinity-matured antibodies produced as a result of the GC response
exert critical control over viral loads and, in some cases, lead to viral control
(Chen et al., 2018; Chou et al., 2016; Doria-Rose et al., 2016; Kinchen et al.,
2018; Seiler et al., 1998). Additionally, non-neutralizing antibodies that
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incompletely control viral replication are required to partially contain infection
(Hangartner et al., 2006; Horwitz et al., 2017; Richter and Oxenius, 2013; Straub
et al., 2013) and can apply selective pressure for viral escape and evolution in
some settings (Doria-Rose et al., 2014; Kinchen et al., 2018; Wu et al., 2015).
Thus, humoral immune responses that occur during chronic infections likely
involve considerable participation of GC B cell responses. Yet, the biology
governing GC B cell differentiation and fate decisions in the setting of chronic
viral infections remains to be elucidated. A better understanding of dysregulated
humoral immunity and GC biology during chronic viral infections could provide
valuable insights to improve vaccination and antibody responses during chronic
viral infections.

1.4 LCMV model system as a tool to mechanistically study
chronic viral infections
Humoral immune dysfunction during chronic viral infections in humans is
well documented and generally defined by the increased production of less avid
antibodies. These observations and additional alterations in peripheral B cell
subsets (Moir et al., 2008; Oliviero et al., 2015) during chronic viral infection
suggest that chronic viral infection may alter B cell differentiation within SLOs
and in particular the GC response. While study of serum antibody and peripheral
B cell subsets have been instrumental in defining humoral immune dysfunction
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during chronic infection, mechanistic study of how chronic viral infection impacts
the GC response has been limited by access to lymphoid tissues in humans.
Thus, modeling chronic viral infection in experimental animal models, such as
mice, provides a more tractable system for increased mechanistic understanding
of the GC response to chronic viral infection.
The LCMV mouse model of viral infection has been an invaluable tool for
understanding anti-viral adaptive immune responses and host-pathogen
interactions. LCMV is a single-stranded negative sense RNA virus of the family
Arenaviridae whose natural reservoir is the mouse. The LCMV genome is
bisegmented and consists of coding segments for 5 viral proteins (Urata and
Yasuda, 2012). Viral entry into cells is mediated through binding of the LCMV
glycoprotein GP-1 to its receptor, a-dystroglycan (Cao et al., 1998; Kunz, 2009).
Due to the broad expression of a-dystroglycan by cells in many tissues, infection
with LCMV is systemic.
Many strains of LCMV exist, but perhaps the most widely used are LCMVArmstrong (LCMV-Arm, acute) which leads to an acute resolving infection and
LCMV-Clone13 (LCMV-Cl13, chronic) which leads to a persistent infection
(Ahmed, 1984; Wherry et al., 2003a). The acute and chronic strains of LCMV
differ by only three amino acids (Matloubian et al., 1990, 1993; Sullivan et al.,
2011), but these mutations allow chronic LCMV to evade immunity and establish
chronicity. A mutation in the LCMV polymerase protein (L protein) allows chronic
LCMV to replicate faster in dendritic cells and macrophages (Matloubian et al.,
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1993). Two additional mutations in the viral glycoprotein GP-1 result in higher
affinity binding of GP-1 to a-dystroglycan allowing increased early infection of
FDCs and disruption of lymphoid architecture (Matloubian et al., 1990; Sullivan et
al., 2011).
Historically, the LCMV model system has been a useful tool to study how
persistent antigen and chronic inflammation alter adaptive immune responses,
particularly in CD8 T cells and within the field of T cell exhaustion (McLane et al.,
2019); however, little is known about how persistent antigen and inflammation
impact humoral immunity. Humoral immune responses to chronic LCMV mirror
many of the immune dysfunctions observed in humans with chronic viral
infections such as HIV or HCV. Chronic LCMV infection causes
hypergammaglobulinemia (Hunziker et al., 2003) and infected mice fail to make
neutralizing antibodies until approximately 100 days post-infection (Battegay et
al., 1993). Similar to HIV, LCMV uses glycan shielding to limit B cell and antibody
access to the neutralizing determinant on GP-1 (Sommerstein et al., 2015).
Despite the delayed development of neutralizing antibodies during chronic LCMV
infection, humoral immunity is critical for viral control as mice without CD4 T cells
or lacking the antibody isotype IgG2a/c fail to control LCMV-CL13 viremia
(Barnett et al., 2016; Matloubian et al., 1994).
Our understanding of how LCMV-CL13 subverts the B cell response is still
poorly understood due to the limited ability to track LCMV-specific B cell
responses. Traditional study of humoral immunity has been focused on antigen19

specific antibodies, but much less attention has been paid to the B cells that
produce those antibodies. This is evident even in the common naming of the two
arms of the adaptive immune system, humoral and cellular. Of course, humoral
immunity is entirely dependent on a form of cellular immunity. However, while
antigen-specific T cell responses have long been studied with the use of
fluorescently labeled pMHC tetramers, until recently B cell specificity remained
limited to either serologic assays of the resulting secreted antibodies or of B cell
ELISPOTS that do not allow for any cellular characterization of the antibodysecreting cell. For B cells that do not yet secrete antibody, few antigen-specific
assays exist. Therefore, one major barrier to the study of cellular aspects of
humoral immunity is the lack of tools to identify virus-specific B cells.
Recent work using LCMV-specific BCR transgenic mice has identified an
alteration of the pre-GC extrafollicular B cell differentiation checkpoint during
chronic LCMV infection (Fallet et al., 2016; Moseman et al., 2016; Sammicheli et
al., 2016). These studies found that chronic LCMV infection causes massive
attrition of LCMV-specific B cell responses through promotion of plasma cell
differentiation, extrafollicular localization, and subsequent deletion by
inflammatory macrophages. However, despite alterations in this pre-GC
checkpoint, mice infected with chronic LCMV still make GCs. Importantly, these
GC responses exert critical pressure during chronic LCMV infection as mice
lacking factors critical for positive selection in the GC fail to control chronic
LCMV. Recently, recombinant protein tools have been developed that allow
identification of LCMV-NP-specific B cell responses (Fallet et al., 2016; Schweier
20

et al., 2019; Sommerstein et al., 2015). Recombinant expression of LCMV-NP in
bacterial systems allows tracking of LCMV-NP-specific B cells in vivo and allows
more careful dissection of the mechanisms underlying humoral immune
dysfunction during chronic infection. Thus, acute and chronic LCMV infection of
mice is an ideal model for the investigation of how chronic infection alters B cell
differentiation.
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CHAPTER 2: Chronic viral infections impair virus-specific
germinal center responses
2.1 Introduction
Effective humoral immune responses to infection and immunization are
defined by high-affinity antibodies generated as a result of B cell differentiation
and selection that occurs within germinal centers (GC) (Cyster and Allen, 2019;
Plotkin, 2008). Within the GC, B cells undergo affinity maturation, an iterative and
competitive process wherein B cells mutate their immunoglobulin genes (somatic
hypermutation) and undergo clonal selection by competing for T cell help (Cyster
and Allen, 2019; Mesin et al., 2016; Shlomchik et al., 2019). Balancing the
decision to remain within the GC and continue participating in affinity maturation
or to exit the GC as a plasma cell (PC) or memory B cell (MB) is critical for
achieving optimal antibody avidity, antibody quantity, and establishing
immunological memory in response to immunization or infection.
As discussed in section 1.3, humoral immunity in chronic viral infections is
often dysregulated with hypergammaglobulinemia is a hallmark of chronic viral
infections such as HIV (Lane et al., 1983; Milito et al., 2004; Moir and Fauci,
2017), HCV (Bjøro et al., 1994; Cashman et al., 2014; Racanelli et al., 2006), a
finding that is consistent with the mouse model of infection with the chronic strain
of LCMV (Hunziker et al., 2003; Oldstone and Dixon, 1969). Despite increased
total antibody titers, the antibodies made during chronic viral infections are poor
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quality, displaying lower affinity maturation compared to acutely resolved
infection and delayed development of virus-neutralizing function (Battegay et al.,
1993; Eschli et al., 2007; Gray et al., 2007; Logvinoff et al., 2004). In addition,
vaccine-induced antibody responses are worse in individuals with pre-existing
chronic viral infections compared to healthy control subjects (McKittrick et al.,
2013; Shive et al., 2018; Wiedmann et al., 2000). Together, these observations
suggest that chronic viral infection may impair B cell differentiation and fate
decisions, leading to dysregulated humoral immunity.
While dysregulated humoral immunity during chronic infection has long
been appreciated, our understanding of the key steps in B cell differentiation and
underlying mechanisms of the dysregulation remains limited. As discussed in
sections 1.4, despite data in mice suggesting that chronic viral infection leads to
loss of the pre-GC B cell, many lines of evidence in human and mice suggest
that humoral immune responses during chronic infections involve considerable
participation of GC B cell responses (Chen et al., 2018; Chou et al., 2016; DoriaRose et al., 2014; Kinchen et al., 2018; Wu et al., 2015). Yet, the serologic output
of the GC remains altered (Battegay et al., 1993; Doria-Rose et al., 2014;
Kinchen et al., 2018; Wu et al., 2015). A better understanding of dysregulated
humoral immunity and GC biology during chronic viral infections could provide
valuable insights to improve vaccination and antibody responses during chronic
infections.
The studies in this chapter interrogate the impact of chronic infection on
the development and differentiation of GC B cell responses. Using novel
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recombinant protein tools to track and characterize the virus-specific B cell
response, we find that chronic infection skews GC B cell differentiation away
from the GC B cell fate and towards the PC and MB fates. Skewing away from
the GC B cell fate during chronic infection was associated with increased virusspecific antibody titers but decreased serum antibody avidity and impaired affinity
maturation. Transcriptional profiling of virus-specific B cell responses identified
enrichment of the PC and MB gene signatures associated with inflammatory
signaling in virus-specific GC B cells during chronic infection. Taken together,
these results indicate that chronic infection skews B cell differentiation away from
the GC B cell fate and towards the PC and MB fates leading to delayed
development of effective antibody responses.

2.2 Methods
2.2.1 Mice
6-8 week old C57BL/6 Ly5.2CR (CD45.1) or C57BL/6 (CD45.2) mice were
purchased from NCI. Both male and female mice were used for these studies in
accordance with NIH guidelines. Mice were maintained in a specific-pathogenfree facility at the University of Pennsylvania. All mice were used in accordance
with Institutional Animal Care and Use Committee guidelines for the University of
Pennsylvania.
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2.2.2 Viral infection
Mice were infected intraperitoneally (ip) with 2*105 plaque-forming units
(PFU) of LCMV-Armstrong (Arm) or intravenously (iv) with 4*106 PFU LCMVCL13 (CL13). LCMV strains were propagated and titers were determined as
previously described (Odorizzi et al., 2015; Wherry et al., 2003b).
2.2.3 LCMV-NP protein production and purification
Expression plasmids encoding a 6x His tagged version of the LCMV
nucleoprotein (NP) (nucleoprotein sequences from LCMV-Arm and LCMV-CL13
have 100% homology) were a kind gift from D. Pinschewer (University of Basel,
Basel, Switzerland) and originally developed by H. Pircher (University of
Freiberg, Germany) and was used as previously described (Fallet et al., 2016;
Schweier et al., 2019; Sommerstein et al., 2015). Briefly, plasmid was
transformed into Rosetta™ 2(DE3) competent cells (Novagen, Millipore Sigma).
Protein expression was induced with .5M IPTG (Sigma) for 24 hours. Bacteria
were harvested after induction, lysed and sonicated. The soluble fraction was
purified over a HiTrap TALON crude column (GE Healthcare) on a GE
AKTAprime plus FPLC system (GE Healthcare). Purified protein was desalted
using PD-10 columns (GE Healthcare) and concentrated prior to use.
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2.2.4 Single cell suspension preparation and LCMV-specific B cell
staining and enrichment.
Single cell suspensions were obtained from spleens by homogenizing
tissues against a 70um cell strainer. Cells were washed through cell strainer and
red blood cells were lysed in ACK lysis buffer (Thermo Fisher Scientific). Cells
were resuspended in MACS buffer (PBS with 1mM EDTA and 2% fetal bovine
serum) prior to cell staining or B cell enrichment. To identify LCMV-specific B
cells, purified LCMV-NP was fluorescently labeled with Alexa Fluor 647 or Alexa
Fluor 488 using antibody labeling kits according to manufacturer’s instructions
(Thermo Fisher Scientific). Single cell suspensions were stained with LCMV-NP
for 15 minutes at 37°C in the presence of Fc-block (anti-CD16/32, 24G2, BD) and
washed twice with MACS buffer prior to staining with additional fluorescent
antibody panels. For bulk RNAseq experiments, B cell enrichment (negative
selection) was performed using mouse pan-B cell isolation kits (Stem Cell
Technologies) according to manufacturer’s instruction except incubation times
were doubled. Following B cell enrichment, LCMV-NP staining was performed as
described above. LCMV-NP-labeled cell suspensions were further enriched
(positive selection) for LCMV-specific B cells by incubating cells with antiCy5/AF647 microbeads (Miltenyi Biotec) followed by purification over LS columns
(Miltenyi Biotec).
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2.2.5 Flow cytometry and cell sorting
Single cell suspensions were prepared and stained with fluorescently
labeled LCMV-NP as described above. Cell suspensions were stained at 4°C for
30 minutes for surface protein staining. Intracellular staining was conducted at
room temperature for 1 hour. Antibodies were purchased from Biolegend:
CXCR4 (L276F12), CD83 (Michel-19), CD86 (GL-1), B220 (RA3-6B2), CD19
(1D3), IgD (11-26c.2a), CD138 (281-2), GL7 (GL7), CD38 (90), F4/80 (BM8),
NK1.1 (PK136), IgM (RMM-1), Ki67 (16A8), CD69 (H1.2F3), Steptavidin-BV786;
BD Biosciences: CXCR4 (2B11), CD83 (Michel-19), CD19, (1D3), CD138 (2812), CD38 (90), CD4 (GK1.5), Blimp1 (5E7), Bcl6 (K112-91), CD31 (MEC 13.3),
CCR6 (140706), Streptavidin BB780; eBioscience (Thermo Fisher Scientific):
GL7 (GL7), CD4 (RM4-5), CD8 (53-6.7), F4/80 (BM8), NK1.1 (PK136); or from
Southern Biotech: Ly6a (D7). Live cells were discriminated by staining with
Live/Dead Aqua (Thermo Fisher Scientific) or Zombie Yellow (Biolegend). For
cell sorting for BCR repertoire analysis, samples were sorted directly into lysis
buffer (RLT or RLT+, Qiagen) or into 10% FBS cRPMI supplemented with 25mM
HEPES. Flow cytometry data were acquired on a BD LSR II instrument or BD
Symphony A3 instrument. Cell sorting was performed on a BD FACSAria
enclosed within a laminar flow hood. Data were analyzed using FlowJo software
(FlowJo, LLC).
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2.2.6 Immunofluorescent microscopy
Mouse spleen samples were acquired from LCMV-Arm and LCMV-CL13
infected mice at day 15 post-infection. Spleens were embedded in Optimal
Cutting Temperature (OCT, Tissue-Tek, VWR) and snap frozen using a 2methylbutane (Sigma) bath over dry ice. 7um sections on slides were stained as
follows. Slides were desiccated at room temperature (RT) for 5-10 minutes prior
to fixation in 4% freshly prepared paraformaldehyde for 10 minutes at RT.
Following fixation, samples were rehydrated in PBS for 5 minutes followed by
blocking for 1 hour in blocking buffer (1% bovine serum albumin (Sigma) and
0.3% Triton X-100 (Sigma)). Fluorescently-conjugated primary antibodies (IgD,
clone 11-26c.2a, Biolegend and GL7, clone GL7, Thermo Fisher Scientific) were
added and incubated for 2 hours at RT. Following incubation with primary
antibodies, samples were wash 3x in PBS followed by coverslip mounting with
ProLong Diamond with DAPI (Thermo Fisher Scientific).
Images were acquired on an inverted DMi8 widefield microscope (Leica)
using a 40x objective (NA 0.95). At least 20 GCs were acquired per sample and
GCs were sampled randomly across each tissue. Analysis of GC area was done
in using the FIJI distribution (Schindelin et al., 2012) of ImageJ (Rueden et al.,
2017) through manual annotation of GC boundaries followed by area
determination.
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2.2.7 Antibody quantification and avidity ELISA
LCMV-specific IgG serum antibody titers were determined using standard
ELISA protocols. Briefly, 96-well MaxiSorp plates (Nunc, Thermo Fisher
Scientific) were coated with 300ng purified recombinant LCMV-NP per well
overnight. For measurement of anti-LCMV-NP serum antibody concentration,
serum samples were assayed in 5-fold dilutions starting from 1:100 dilution and
plated in quadruplicate on each plate. LCMV-NP-specific IgG was detected using
biotin-conjugated goat-anti-mouse IgG(H+L) (Southern Biotech) followed by
incubation with streptavidin-HRP (Southern Biotech) and developed with
tetramethylbenzidine (Thermo Fisher Scientific). Amount of antibody in each
serum sample was calculated by fitting a standard curve generated using an antiLCMV-NP monoclonal antibody (VL4, BioXcell).
Antibody avidity was measured by ELISA with modifications (Nawa, 1992;
Pullen et al., 1986). For serum antibody avidity measurements, the anti-LCMVNP ELISA was modified to include a wash step with either PBS, 1.5M sodium
thiocyanate (NaSCN), 3M NaSCN, or 4.5M NaSCN for 15 minutes at room
temperature after incubation of serum samples but before application of
secondary goat-anti-mouse IgG(H+L) antibody. Avidity index was calculated as
follows: Avidity index = (OD450NaSCN/OD450PBS)*100. Serum samples for serum
avidity measurements were diluted to a concentration yielding OD450 of
approximately 1 prior to incubation with NP-coated ELISA plates.
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2.2.8 B cell receptor sequencing (BCRseq)
All LCMV-NP-specific B cells were first sorted for yield then for purity from
individual mice. Between 3.8k and 28k cells were obtained per sample. Samples
were sorted into buffer RLT (Qiagen) + supplemented with b-mercaptoethanol
(Sigma) and processed with an AllPrep DNA/RNA Micro Kit (Qiagen) according
to manufacturer’s recommended protocol. Genomic DNA was sent to the Human
Immunology Core at the University of Pennsylvania for mouse antibody heavy
chain library construction, sequencing and data analysis. Primers used were
adapted from Wang et. al (Wang et al., 2000) and were modified to include
adaptor sequences for the Illumina NexteraXT kit and are as follows:

MH1 primer
5’TCGCGAGTTAATGCAACGATCGTCGAAATTCGCSARGTNMAGCTGSAGSAG
TC-3’;
JH1/4
5’ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTANTGAGGAGACGGTG
AC-3’;
JH2
5’ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGAGGAGACTGTGAGAG
TGG-3’.
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Amplicons were purified using the Agencourt AMPure XP beads system
(Beckman Coulter, Inc., Indianapolis, IN), and quantified by Qubit Fluorometric
Quantitation (Thermo Fisher Scientific, Grand Island, NY). Libraries were
loaded onto an Illumina MiSeq and 2x300 bp paired end kits were used for all
experiments (Illumina MiSeq Reagent Kit v3, 600 cycle, Illumina Inc., San Diego,
Cat. No. MS-102-3003).
Raw sequence data (FASTQ files) were processed through pRESTO
v0.5.3 (Vander Heiden et al., 2014) and any sequence with a 10 bp section that
had an average Phred quality score lower than 30 was removed, along with any
sequence that was shorter than 100 bases. Germline V and J genes were
identified by aligning pre-processed data to the murine IgH germline repertoire
using the IMGT/HighV-QUEST tool hosted by the International Immunogenetics
Information Systems (IMGT, imgt.org) (Alamyar et al., 2012; Lefranc et al., 2015;
Li et al., 2013). Aligned reads were further processed with Change-O v0.4.5
(Gupta et al., 2015). The Change-O processing pipeline included filtering nonfunctional sequences and clustering sequences into clonal lineages. Data were
then filtered by calculating the mean frequency (copy number) of all clones and
selecting for clonal lineages above 50% of the mean copy number frequency.
The frequency of mutation from germline, replacement to silent ratios (R/S ratio),
and selection pressure (BASELINE, (Yaari et al., 2012)) were calculated using
SHazaM v0.1.11 (Gupta et al., 2015).
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2.2.9 Bulk RNAseq sample preparation
To assess the kinetic transcriptional differences between LCMV-specific B
cell subsets responding to LCMV-Arm or LCMV-CL13 infection, LCMV-specific
GC B cells (CD38-GL7+), memory B cells (CD38+GL7-), and plasma cells
(CD138+) were sorted from mice infected with LCMV-Arm or LCMV-CL13 at
days 7, 15, and 45 post-infection. All B cell subsets were first gated as LCMVLCMV-SPECIFICIgD-B220+Dump- prior to subset-specific gating. Dump gate
included CD4, CD8, NK1.1, and F4/80. Naïve B cells were sorted from
uninfected mice. Samples were sorted first for yield then for purity. 5-10 spleens
were pooled for each of the 3 replicates sequenced at each timepoint. Prior to
sorting, samples were enriched for LCMV-specific B cells and stained with
surface antibodies as previously described. Sorted samples were stored in Buffer
RLT supplemented with b-mercaptoethanol until RNA isolation. RNA isolation
was performed with a RNeasy Mico Kit (Qiagen) per the manufacturer’s
instructions. Library preparation was performed using a SMART-Seq v4 Ultra
Low Input RNA kit (Takara) and Nextera XT DNA Library Preparation Kit
(Illumina) per the manufacturer’s instructions. Quality of extracted RNA and
prepared libraries were assessed using a TapeStation 2200 instrument (Agilent).
Libraries were quantified using a KAPA Library Quantification Kit (Kapa
Biosystems) prior to sequencing on an Illumina NextSeq 550 instrument (150bp,
paired-end, 300 cycle high output flowcells).
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2.2.10 Bulk RNAseq data processing and analysis
FASTQ files were aligned using STAR 2.5.2a (Dobin et al., 2013)to the
GRCm38-p5 murine reference genome (GENCODE, (Frankish et al., 2019)).
Unique mapped reads were normalized using PORT v0.8.4-beta gene-based
normalization (https://github.com/itmat/Normalization). Following PORT
normalization, all downstream processing was conducted using R (R Core Team,
2019).Differential gene expression analysis was performed using Limma (Ritchie
et al., 2015). Limma-voom was used to identify significantly different genes
between groups using p value < 0.05. Ig genes were removed from each sample
prior to differential gene expression analysis. Optimal K values for K-means
clustering was calculated using the consensus K values calculated using the
Elbow, Silhouette, and Gap Statistic methods of the NbClust package (Charrad
et al., 2015). Heatmaps depict all differentially expressed genes (p value < 0.05
and log2 fold change > 2) within LCMV-specific B cell subsets between samples
isolated from LCMV-Arm and LCMV-CL13 infected mice at days 7, 15, and 45
post-infection. Z-score values for genes in each cluster were calculated using the
pheatmap package v1.0.12 (Kolde, 2019), averaged for each timepoint and
infection, then plotted over time. Cluster Gene Ontology (GO) Biological Process
term enrichment was performed using Metascape v3.0 (Zhou et al., 2019) with a
minimum overlap of 3, p value cutoff of 0.01, and a minimum enrichment of 1.5.
Gene set enrichment analysis (GSEA) was performed for gene sets of interest
(Liberzon et al., 2015; Subramanian et al., 2005). Hallmark gene sets were
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obtained from MSigDB (Liberzon et al., 2015). GC B cell signature and spleen
plasma cell signatures in were created using data deposited in the Gene
Expression Omnibus (GEO, GSE60927, (Shi et al., 2015)). Briefly, gene
signatures were generated by determining the top 200 differentially expressed
genes between follicular B cells and subsets of interest as described above.
Memory B cell signatures (Bhattacharya et al., 2007) and LZ and DZ GC B cell
signatures (Victora et al., 2010) were previously published. Plots were made
using ggplot2 (Wickham et al., 2019), the viridis package (Garnier, 2018), and
the tidyverse package (Wickham, 2017).

2.3 Results
2.3.1 Chronic infection promotes terminal B cell differentiation
Humoral immunity in chronic viral infections is dysregulated and often
associated with poor immunity. These defects in B cell responses are
characterized by hypergammaglobulinemia, altered B cell differentiation, and the
delayed development of neutralizing antibodies (Battegay et al., 1993; Bjøro et
al., 1994; Cashman et al., 2014; Eschli et al., 2007; Gray et al., 2007; Hunziker et
al., 2003; Lane et al., 1983; Logvinoff et al., 2004; Milito et al., 2004; Moir and
Fauci, 2017; Oldstone and Dixon, 1969; Racanelli et al., 2006). Despite these
observations, it has remained challenging to quantify the virus-specific B cell
response to chronic viral infections and track numerical changes and
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differentiation over time. Previous studies in the mouse model of chronic LCMV
infection identified a major detrimental effect of excessive IFN-I signaling causing
profound B cell attrition at early time points (days 0-3) that led to defects in
subsequent humoral immunity (Fallet et al., 2016; Moseman et al., 2016;
Sammicheli et al., 2016). Despite these early B cell defects, germinal centers
(GC) still form during chronic infections (Barnett et al., 2016; Clingan and
Matloubian, 2013; Daugan et al., 2016; Fukazawa et al., 2015) and the biology of
GC responses during these persisting infections remains poorly understood. To
begin to dissect these questions, we interrogated the LCMV-specific B cell
response to acutely resolved (LCMV Armstrong; Arm) versus chronic (LCMV
clone 13) LCMV infection. We identified LCMV-NP-specific B cells using
fluorescently labeled bacterially-produced LCMV nucleoprotein (NP) as
previously described (Figures 2.1A and 2.2A) (Fallet et al., 2016; Schweier et
al., 2019). Although LCMV-NP-specific antibodies are not neutralizing, NP is the
dominant target of the LCMV-specific antibody responses (Battegay et al., 1993).
NP protein sequences are identical between the acute and chronic strains of
LCMV allowing control for strain-specific differences in other LCMV viral proteins
(Matloubian et al., 1990, 1993; Sullivan et al., 2011). Acute or chronic LCMV
infection resulted in similar frequencies of LCMV-specific B cells during the first
7-10 days of infection (Figure 2.1B). However, by day 15 post-infection (pi)
LCMV-specific B cells increased in frequency and total number following LCMV
Arm infection but remained lower in magnitude during chronic LCMV infection
(Figure 2.3A). These data indicated that chronic infection resulted in decreased
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frequency of virus-specific B cells during the timepoints when the GC and
memory B (MB) cell responses are developing.
Tight regulation of B cell differentiation into GC B cells, plasma cells (PC)
and memory B cells (MB), is critical for achieving optimal antibody avidity,
antibody quantity, and immunological memory, respectively. Thus, to define the
LCMV-specific B cell response in more detail, we used markers to distinguish PC
(CD138+), GC B cells (CD38-GL7+) and MB (CD38+GL7-) at day 15 pi (Figures
2.1C and 2.2A). In acute infection, approximately 80% of the NP-specific B cells
were GC phenotype at this time point (Figure 2.1C-D). In contrast, during chronic
infection there were four-fold fewer NP-specific GC B cells whereas PC and MB
frequencies were increased 10-fold and two-fold, respectively (Figure 2.1C-D).
The reduced frequency of GC B cells was not due to an absence of GCs during
chronic infection, and the GCs that were present were similar in size to those
observed following acute infection (Figure 2.3B). Thus, at the peak of the virusspecific B cell response, the distribution of NP-specific B cell responses during
chronic infection was skewed towards the PC and MB fates and away from the
GC B cell fate.
Longitudinal analysis of these NP-specific B cell responses during acute
or chronic infection revealed differences in the magnitude and kinetics of PC, GC
B cell and MB (Figure 2.1E-G and 2.3C-E). Whereas PC and MB responses
were increased during chronic infection, especially during the second and third
week of infection, GC B cell frequencies were substantially lower during this time
frame. These data reveal a sustained quantitative defect in the overall virus36

specific B cell response during chronic infection, but also identify differences in
PC, MB and GC responses over time. Collectively, these data suggest that
chronic infection promotes early induction of PC and MB responses at the
expense of the GC response.

37

Figure 2.1

Figure 2.1: Chronic infection promotes terminal B cell differentiation.
(A) Representative FACS plots of splenic LCMV-NP-specific B cell staining in
naïve, LCMV-Arm (Acute), and LCMV-CL13 (Chronic) infected mice at d15 post
infection. Cells were previously gated as IgD-B220+Dump-. Dump gate includes
CD4, CD8, F4/80, and NK1.1. (B) Frequency of splenic LCMV-NP-specific B
cells in LCMV-Arm and LCMV-CL13 infected mice at days 7, 10, 15, 21, 35, and
110 post-infection. (C) Representative FACS plots of splenic LCMV-specific
plasma cells, germinal center B cells, and memory B cells in LCMV-Arm and
LCMV-CL13 infected mice at d15 post infection. Cells were previously gated on
LCMV-specific B cells as described in A. (D) Frequency of splenic plasma cells,
germinal center B cells, and memory B cells in LCMV-Arm and LCMV-CL13
infected mice at d15 post-infection. (E-G) Kinetics of LCMV-specific splenic
plasma cell (E), germinal center B cell (F), and memory B cell (G) frequencies in
LCMV-Arm and LCMV-CL13 at days 7, 10, 15, 21, 35, and 110 post-infection.
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Each data point in B, E-G and H-J shows mean ± SEM with 3-5 mice per time
point from two independent experiments. Data points in D show mean ± SEM
from 10 mice pooled from two independent experiments. *p<0.05, **p<0.01,
***p<0.001, Student’s t-test
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Figure 2.2

Figure 2.2: Gating and sort strategies for analysis of LCMV-specific B cells
(A) Gating strategy for identifying LCMV-specific B cells and LCMV-specific GC
B cells, MB, and PC. Cells are first gated for live lymphocyte singlets before B
cell gating. (B) Purification and FACS sorting strategy used for Figures 2.4, 2.5,
(BCR sequencing, bulk RNAseq, and scRNA-seq). Strategy is as follows: 1) Bulk
splenocytes are first negatively selected for pan-B cells using magnetic depletion,
2) Enriched B cells are stained with AF647-conjugated LCMV-NP and magnetic
positive selection is done using anti-AF647 microbeads, 3) Enriched LCMVspecific B cells are then stained for FACS sorting and sorted for yield, 4) Yield40

sorted LCMV-specific B cells are finally sorted for purity and populations of
interest. Representative FACS plots depict B cell and LCMV-specific B cell
frequencies following each step in the purification process.
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Figure 2.3

Figure 2.3: LCMV-specific B cell responses are diminished during chronic
infection. Related to Figure 2.1.
(A) Enumeration of LCMV-specific B cell response in LCMV-Arm and LCMVCL13 at days 7, 10, 15, 21, 35, and 110 post-infection. (B) 40x images of GCs in
LCMV-Arm and LCMV-CL13 infected mice at day 15 post-infection. GC size was
quantitated for two individual spleens per infection by staining IgD (red) and GL7
(blue). At least 20 GCs per sample were enumerated. Size was manually
determined by marking border between IgD+ cells in the follicular mantle zone
and GL7+ cells within the GC as depicted by yellow dashed line in representative
images. (C-E) Enumeration of LCMV-specific splenic plasma cell (C), germinal
center B cell (D), and memory B cell (E) in LCMV-Arm and LCMV-CL13 at days
7, 10, 15, 21, 35, and 110 post-infection. Each data point in A and C-D shows
mean ± SEM with 3-5 mice per time point from two independent experiments.
Data points in D show mean ± SEM from 10 mice pooled from two independent
experiments. *p<0.05, **p<0.01, ***p<0.001, Student’s t-test
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2.3.2 Affinity maturation is impaired during chronic infection.
Germinal centers are the primary location of affinity maturation, a cyclic
process by which B cells mutate their immunoglobulin genes, compete for
antigen and T cell help, and undergo clonal expansion following positive
selection (Cyster and Allen, 2019; Mesin et al., 2016). Previous studies have
shown that accumulation of affinity-enhancing mutations is critical for eventual
control of viremia during chronic LCMV infection (Chen et al., 2018; Chou et al.,
2016). However, the delayed production of neutralizing antibody during chronic
LCMV infection suggests the process of affinity maturation is dysregulated, an
alteration that may also occur during other chronic infections (Battegay et al.,
1993; Doria-Rose et al., 2014; Eschli et al., 2007; Kinchen et al., 2018;
Minamitani et al., 2015; Wu et al., 2015). Based on the data above showing
reduced LCMV-specific GC B cells during chronic infection but increased LCMVspecific PC, we hypothesized that chronic infection might increase the overall
quantity of LCMV-specific antibodies but impair affinity maturation and therefore
serum antibody avidity. We first measured serum LCMV-specific antibody titers
using an LCMV-NP-specific ELISA. Consistent with our previous longitudinal flow
cytometry analysis of LCMV-specific PC, LCMV-NP-specific IgG titers were
increased during chronic infection at day 7 pi (prior to initiation of the GC
response) and at all timepoints measured after d21 pi (Figure 2.4A). We next
sought to determine whether LCMV-specific serum antibody avidity was
impacted by chronic infection. Thus, we measured LCMV-specific serum
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antibody avidity using an ELISA combined with a chaotropic sodium thiocyanate
(NaSCN) wash to remove low avidity antibody (Nawa, 1992; Pullen et al., 1986).
In this assay, antibody avidity (Avidity Index) was measured by comparing the
fraction of serum antibody sensitive to removal by NaSCN treatment to total
antibody levels (Figure 2.5A). Following acute infection, the avidity index
increased with time post infection indicating affinity maturation and development
of high avidity antibody (Figures 2.4B and C). Serum antibody avidity increased
following the formation of the LCMV-specific GC response following acute
infection, starting at day 10 and plateaued at day 45 pi. In contrast to acute
infection, the development of avid antibodies was delayed in chronic infection.
The avidity indices of the LCMV-specific antibody response were similar between
acute and chronic infection at early time points pi but began to diverge at day 35
pi with lower avidity antibodies present during chronic infection. Thus, chronic
infection impairs and/or delays the development of highly avid antibodies.
Given that accumulation of mutations in immunoglobulin genes is critical
for driving affinity maturation (Mesin et al., 2016; Muramatsu et al., 2002;
Odegard and Schatz, 2006), we measured heavy chain B cell receptor (BCR)
repertoire usage and mutation levels by sequencing BCR genes from LCMVspecific B cells at day 45 pi. VH gene family usage was similar between LCMVspecific B cells in acute and chronic infection, in both cases favoring the use of
the VH1 gene family (60% of all clones), in particular VH1-82 (Figures 2.4D and
2.5B). While VH gene usage was similar, the accumulation of mutations during
acute and chronic infection was distinct. LCMV-specific B cells in acute infection
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were approximately 2.5% mutated from their germline VH gene sequence,
whereas LCMV-specific B cells in chronic infection were only 1.5% mutated from
germline (Figure 2.4E and 2.5D). In chronic infection decreased BCR mutations
occurred preferentially in the complementarity determining regions (CDR) 1 and
2, but not in the framework regions (Figure 2.5E). Additionally, mutations
resulting in amino acid replacements were also decreased in the CDR regions
during chronic infection (Figure 2.5F). We next applied the BASELINe algorithm
(Yaari et al., 2012) to quantify selection pressure in the CDR and framework
regions. BCR sequences from LCMV-specific B cells in chronic infection had less
positive selection in the CDRs than in acute infection (Figure 2.4E). Collectively,
these data suggest that chronic infection impairs antibody affinity maturation by
decreasing the accumulation of affinity-enhancing mutations during somatic
hypermutation in the GC.
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Figure 2.4

Figure 2.4: Affinity maturation is impaired during chronic infection.
(A) Kinetic measurement of serum LCMV-NP-specific IgG titers in LCMV-Arm
and LCMV-CL13 infected mice at days 7, 10, 15, 21, 35, and 110 post-infection.
(B) Anti-LCMV-NP serum avidity index measurements in LCMV-Arm and LCMV
CL13 infected mice at days 15 and 45 post-infection using chaotropic NaSCN
ELISA. Dose response to increasing amounts of the chaotropic agent NaSCN is
depicted. (C) Anti-LCMV-NP serum avidity index in response to 1.5M NaSCN in
LCMV-Arm and LCMV-CL13 infected mice at days 7, 10, 15, 21, 35, and 110
post-infection. (D) Heavy chain VH family usage in LCMV-specific B cell BCR
repertoires from LCMV-Arm and LCMV-CL13 infection mice at d45 post-infection.
Each point represents one mouse. Data representative of two independent
experiments. (E) Frequency of mutation in the heavy chain VH genes in LCMVArm and LCMV-CL13 infected mice at d45 post-infection. Data represent VH
germline mutation frequency of one representative sequence from each
clonotype. Data are pooled from IgH BCR repertoires of 5 individual mice per
infection. ****p<0.0001, Mann-Whitney U-test of medians. (F) Selection pressure
(S) in IgH CDR and FWR measured by BASELINE algorithm. Data are pooled
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from IgH BCR repertoires of 5 individual mice per infection. ***p<0.001, Student’s
t-test.
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Figure 2.5

Figure 2.5: Chronic infection impairs affinity maturation but BCR repertoire
usage is largely unaffected. Related to Figure 2.4
(A) Anti-LCMV-NP serum avidity index in response to NaSCN treatment in
LCMV-Arm and LCMV-CL13 infected mice at days 7, 10, 15, 21, 35, and 110
post-infection. (B) Heavy chain VH1 gene usage in LCMV-specific B cell BCR
repertoires from LCMV-Arm and LCMV-CL13 infection mice at d45 post-infection.
Each point represents one mouse. Data representative of two independent
experiments. (C) Frequency of heavy chain BCR repertoire represented by the
20 most abundant clonal families from LCMV-Arm and LCMV-CL13 infection
mice at d45 post-infection. (D) Plot of BCR family clonal abundance by average
mutation frequency. (E) Frequency of heavy chain mutations in broken down by
heavy chain region. Complementarity determining region (CDR) and framework
(FWR). (F) Frequency of replacement and silent mutations in BCR repertoires
analyzed. Data are pooled from IgH BCR repertoires of 5 individual mice per
infection. ***p<0.001, Student’s t-test.
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2.3.3 Distinct molecular profiles of LCMV-specific GC, PC and MB
during chronic infection.
Chronic infection promotes unique transcriptional programs and
differentiation states in CD8+ and CD4+ T cells (Crawford et al., 2014; Doering et
al., 2012), but it is unclear whether chronic infection impacts transcriptional
programs of antigen-specific B cells and if so, how . To interrogate this question,
we sorted LCMV-specific GC B cells, PC, and MB at days 7, 15, and 45 pi during
acute and chronic infection (Figure 2.2B) and performed RNA-seq. In general,
each LCMV-specific B cell population (GC B cells, PC, and MB) clustered by day
pi in principle component space (Figure 2.6A). For all three cell types,
transcriptional profiles were most similar at day 7 pi. For PC and MB,
transcriptional programs diverged over time with the greatest difference in RNAseq apparent at d15 or 45 p.i (Figure 2.7A-C). However, the largest
transcriptional divergence between acute and chronic infection occurred for GC B
cells at day 15 pi (Figure 2.6B). Indeed, differential gene expression analysis
identified 346 genes differentially expressed between LCMV-specific GC B cells
at day 15. 311 of the 346 differentially expressed genes at day 15 pi were
upregulated during chronic infection. In LCMV-specific GC B cells at day 15 pi,
acute infection enriched for genes related to B cell homeostasis (Bcl6, Lyn, and
Tnfrsf13c), cellular response to DNA damage stimulus (Aicda, Foxo1, H2afx, and
Gadd45b), and histone H3 acetylation (Brd1 and Hdac4) whereas chronic
infection enriched for genes related to response to virus (C1qbp and Tlr7),
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response to interferon-b and interferon-a (Irf1, Stat1, Bst2, and Ifi204), and
response to biotic stimulus (Prdm1, Ptpn22, and Mif) (Figure 2.6C, 2.6D and
2.7D-F). We observed approximately 12-fold increased expression of the PC
master regulatory transcription factor Prdm1 and 1.6-fold repression of Bcl6, the
key transcriptional regulator of GC B cell fate, during chronic infection suggesting
that chronic infection may promote excessive LCMV-specific GC B cell
differentiation towards the PC fate (Figure 2.6E). Together these data suggested
that LCMV-specific GC B cells have divergent transcriptional programs at day 15,
and expression of key transcription factors pointed to potentially altered GC B
cell fate decisions.
Given that the greatest difference in transcriptional profiles occurred in GC
B cells at day 15 pi, we next investigated the impact of chronic infection on the
program of these cells in more detail. The GC is comprised of two anatomical
zones where GC B cells undergo selection (light zone; LZ) and accumulate
mutations through proliferation (dark zone; DZ). Given the data above on altered
accumulation of affinity-enhancing mutations in the BCR during chronic infection,
we hypothesized that chronic infection may disrupt the LZ to DZ balance for
virus-specific B cells. Using Gene Set Enrichment Analysis (GSEA)
(Subramanian et al., 2005), we compared LCMV-specific GC B cells from acute
and chronic infection to known antigen-specific GC B cell LZ and DZ gene
signatures (Victora et al., 2010). In chronic infection, LCMV-specific GC B cells
were enriched for the LZ gene signature whereas LCMV-specific GC B cells in
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acute infection were enriched for the DZ (Figure 2.6F and 2.6G) suggesting an
altered GC distribution of virus-specific B cells in chronic infection. Selection into
the DZ is driven by Myc and the mTORC1 complex following positive selection in
the LZ (Calado et al., 2012; Dominguez-Sola et al., 2012; Ersching et al., 2017;
Finkin et al., 2019; Luo et al., 2018). The mTORC1 signaling gene signature was
enriched in chronic infection however, the Myc target gene signature was
unchanged between acute and chronic infection (Supplemental Table 1). Given
the critical role for mTORC1 signaling in plasma cell differentiation (Benhamron
et al., 2015; Jones et al., 2016) and increased expression of Prdm1 and
decreased expression of Bcl6 noted in Fig 2.6E during chronic infection, we next
compared LCMV-specific GC B cells from acute and chronic infection to known
antigen-specific GC B cell, PC and MB gene signatures using GSEA
(Bhattacharya et al., 2007; Shi et al., 2015). In agreement with the flow
cytometric data in Fig 2.1D and transcription factor data in Fig 2.6E, LCMVspecific GC B cells from acute infection enriched for the GC B cell signature but
not the PC or MB signatures (Figure 2.6H-J). In contrast, LCMV-specific GC B
cells in chronic infection enriched for the PC and MB cell signatures, but not the
GC B cell signature. Collectively, these data indicate that chronic infection
promotes a PC and MB cell transcriptional signature within GC B cells perhaps
indicating early terminal differentiation within the GC in chronic infection.
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Figure 2.6

Figure 2.6: Distinct molecular profiles of LCMV-specific GC, PC and MB
during chronic infection.
(A) PCA plot of LCMV-specific GC B cells, PC, and MB at day 7, 15, and 45
post-infection. (B) Number of significant differentially expressed genes (p<0.05
and >2 log fold-change) between LCMV-specific GC B cells, PC, and MB from
LCMV-Arm and LCMV-CL13 infected mice at the indicated timepoints postinfection. (C) Heatmap depicting top 35 and bottom 50 differentially expressed
(p<0.05 and >2 log fold-change) genes between LCMV-specific GC B cells from
LCMV-Arm and LCMV-CL13 infected mice at day 15 post-infection. (D) Top 10
GO terms enriched in LCMV-specific GC B cells from LCMV-Arm and LCMVCL13 infected mice at day 15 post-infection. Color of points represents p-value
significance. Size of point represents percent of cluster genes enriched in each
respective GO term. (E) mRNA normalized counts of Bcl6 and Prdm1 in LCMVspecific GC B cells from LCMV-Arm and LCMV-CL13 at day 15 pi. (F) GSEA plot
of light zone gene signature in LCMV-specific GC B cells from LCMV-Arm and
LCMV-CL13 infected mice at day 15 post-infection. (G) GSEA plot of dark zone
gene signature in LCMV-specific GC B cells from LCMV-Arm and LCMV-CL13
infected mice at day 15 post-infection. (H) GSEA plot of GC B cell gene signature
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in LCMV-specific GC B cells from LCMV-Arm and LCMV-CL13 infected mice at
day 15 post-infection. (I) GSEA plot of PC gene signature in LCMV-specific GC B
cells from LCMV-Arm and LCMV-CL13 infected mice at day 15 post-infection.
(J) GSEA plot of MB gene signature in LCMV-specific GC B cells from LCMVArm and LCMV-CL13 infected mice at day 15 post-infection.
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Figure 2.7

Figure 2.7: Transcriptional regulation of LCMV-specific GC B cells, PC, and
MB is temporally dynamic
(A) Heatmap depicting all differentially expressed (p<0.05 and >2 log foldchange) genes between LCMV-specific GC B cells from LCMV-Arm and LCMV54

CL13 infected mice at days 7, 15, or 45 post-infection. Selected genes are
shown. Heatmaps were k-means clustered and average z-scores for each cluster
were plotted over time for each infection. (B) Heatmap depicting all differentially
expressed (p<0.05 and >2 log fold-change) genes between LCMV-specific
plasma cells from LCMV-Arm and LCMV-CL13 infected mice at days 7, 15, or 45
post-infection. Selected genes are shown. Heatmaps were k-means clustered
and average z-scores for each cluster were plotted over time for each infection.
(C) Heatmap depicting all differentially expressed (p<0.05 and >2 log foldchange) genes between LCMV-specific memory B cells from LCMV-Arm and
LCMV-CL13 infected mice at days 7, 15, or 45 post-infection. Selected genes are
shown. Heatmaps were k-means clustered and average z-scores for each cluster
were plotted over time for each infection. (D) Top 5 GO terms enriched in each
GC B cell cluster identified in C. Color of points represents p-value significance.
Size of point represents percent of cluster genes enriched in each respective GO
term. (E) Top 5 GO terms enriched in each plasma cell cluster identified in C.
Color of points represents p-value significance. Size of point represents percent
of cluster genes enriched in each respective GO term. (F) Top 5 GO terms
enriched in each memory B cell cluster identified in C. Color of points represents
p-value significance. Size of point represents percent of cluster genes enriched in
each respective GO term.
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2.4 Discussion
In the studies outlined in this chapter, we used novel recombinant protein
probes to interrogate the virus-specific B cell response in the LCMV mouse
model of chronic viral infection (Sammicheli et al., 2016; Schweier et al., 2019;
Sommerstein et al., 2015). We found that chronic viral infection skews GC B cell
differentiation towards the PC and MB fates and away from the GC B cell fate.
Skewing away from continued participation in the GC reaction was associated
with decreased serum antibody avidity and impaired affinity maturation. Previous
studies have identified altered B cell differentiation during chronic viral infection
prior to the establishment of the GC (Fallet et al., 2016; Moseman et al., 2016;
Sammicheli et al., 2016). Our results identify a novel role for chronic infection in
altering B cell differentiation after the establishment of the GC response and may
explain why impaired affinity maturation is often observed during chronic viral
infection.
Transcriptional profiling of virus-specific B cell responses during acute and
chronic viral infection identified upregulation of the PC and MB gene programs in
GC B cells during chronic infection. Upregulation of these gene signatures was
correlated with strong evidence of inflammatory signaling and suggested that
inflammation may play a role in skewing B cell differentiation away from the GC B
cell fate and towards the PC and MB fates. Inflammatory signaling is known to
impact B cell differentiation prior to the GC (Fallet et al., 2016; Moseman et al.,
2016; Sammicheli et al., 2016) but it is thought that GC B cell responses are less
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sensitive to inflammatory signaling than naïve B cells due to their decreased
expression of receptors for many mediators of inflammation (immgen.org, (Heng
et al., 2008)). While our studies point to type I and type II interferon signaling as
key regulators of skewed GC B cell differentiation, we cannot point to one
inflammatory cytokine that was causal for the observed phenotype. Persistent
inflammation during chronic infection is complex and multivariable (Stelekati and
Wherry, 2012; Zuniga et al., 2015). Further interrogation of the inflammatory
profile of chronic viral infection will be necessary to fully tease this apart.
Chronic viral infections present a unique challenge to the humoral immune
response due to the presence of both persistent inflammation and chronic
antigen (Virgin et al., 2009). While we observe an impact of inflammation on
shaping virus-specific GC responses, we cannot discount the impact of chronic
antigen exposure. B cell differentiation decisions are regulated in part by BCR
affinity for antigen which involves both a signaling component and an antigen
capture component (Gitlin et al., 2014; Ise and Kurosaki, 2019; Luo et al., 2018;
Shlomchik et al., 2019). It is likely that low-affinity but frequent signaling through
the BCR may appear to a GC B cells as a “high-affinity signal”. High affinity B
cells are preferentially recruited into the PC fate (Phan et al., 2006) and we
observed increased PC differentiation during chronic viral infection consistent
with this model. Whether inflammatory signaling or signals from antigen play a
more important role in shaping B cell differentiation warrant future study.
Taken together, the studies from this chapter suggest that promotion of B
cell terminal differentiation rather than the GC fate may explain why humoral
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immune responses to chronic infection display hypergammaglobulinemia and
delayed development of neutralizing antibodies.
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CHAPTER 3: Transcriptional regulation of germinal center
responses during acute and chronic viral infection
3.1 Introduction
Balancing the decision to remain within the GC and continue participating
in affinity maturation or to exit the GC as a plasma cell (PC) or memory B cell
(MB) is critical for achieving optimal antibody avidity, antibody quantity, and
establishing immunological memory in response to immunization or infection.
Chapter 2 demonstrated that chronic infection alters this balance in favor of the
MB and PC fates. However, the exact signals that regulate this GC B cell
differentiation checkpoint are currently unclear. Given the link between BCR
signal strength and GC B cell differentiation (Phan et al., 2006), it is likely that
chronic antigen during chronic viral infection promotes GC B cell differentiation
into PC and GC exit. Previous studies have identified a critical role for BCR
affinity in regulating this differentiation decision with GC B cells bearing high
affinity receptors undergoing PC differentiation whereas those with low affinity
receptors favor the MB fate. GC B cells with “just-right” BCR affinity undergo
positive selection and DZ reentry (Ise et al., 2018; Kräutler et al., 2017; Laidlaw
et al., 2017; Suan et al., 2017a).
Given the link between BCR signal strength and GC B cell differentiation
discussed in Chapter 1.2.3, it is possible that chronic antigen alone promotes GC
B cell differentiation into PC and GC exit. However, our RNA Sequencing work in
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GC B cells during acute and chronic infection demonstrated a marked
inflammatory signal in day 15 GC B cells responding to chronic virus (Figure
2.6). The relative role of chronic antigen vs chronic inflammation on the GC B cell
response remains unknown.
The studies in this chapter interrogate the impact of chronic infection on
GC B cell fate decisions. Using scRNAseq of virus-specific GC B cells, we
identify a key GC B cell checkpoint that is dysregulated during chronic infection.
Specifically, during chronic viral infection, GC B cells inefficiently re-enter the
dark zone during the cyclic GC reaction and instead GC B cell fate is skewed
towards premature exit as MB or terminal PC. This short-circuiting of the cyclic
process of GC B cell development occurred at a single light zone step in GC B
cell differentiation. Single cell profiling pointed to attenuated BCR signaling and
CD40 signaling, but amplified inflammatory signals were also associated with this
altered GC developmental pattern. Manipulation of CD40 signals, antigen, and
inflammation identified a dominant role for persistent inflammation over antigen in
skewing GC B cell differentiation during chronic infection. Thus, persistent
inflammation during chronic infection promotes GC B cell differentiation and GC
exit leading to impaired humoral immunity.
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3.2 Methods
3.2.1 Mice
6-8 week old C57BL/6 Ly5.2CR (CD45.1) or C57BL/6 (CD45.2) mice were
purchased from NCI. Both male and female mice were used for these studies.
Ifnarflox/flox (Prigge et al., 2015) and CD19-cre+/+ (Rickert et al., 1997) were
purchased from Jackson Laboratory (strain numbers 028256 and 006785,
respectively). Ifnarflox/floxCD19-cre+/wt mice were generated by breeding Ifnarflox/flox
and CD19-cre+/+ mice and were maintained in our colony. Mice were maintained
in a specific-pathogen-free facility at the University of Pennsylvania. All mice
were used in accordance with Institutional Animal Care and Use Committee
guidelines for the University of Pennsylvania.

3.2.2 Infections and antibody treatments.
Mice were infected intraperitoneally (ip) with 2*105 plaque-forming units
(PFU) of LCMV-Armstrong (Arm) or intravenously (iv) with 4*106 PFU LCMVCL13 (CL13). LCMV strains were propagated and titers were determined as
previously described (Odorizzi et al., 2015; Wherry et al., 2003b). For IFNAR
blockade experiments, mice were treated with anti-mouse IFNAR-1 (MAR1-5A3,
BioXcell) as previously described starting at d13 (Wilson et al., 2013a). For CD40
blockade experiments, mice were treated with 200ug ip anti-mouse CD40L
(MR1, Bioxcell) or 25ug ip anti-mouse CD40 (FGK45, Bioxcell). For BCR
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inhibition experiments, ibrutinib (MedChem Express) was dissolved in Captex355
(Abitec) at 1.25 mg/ml and mice were treated with 250ug of ibrutnib per dose.

3.2.3 LCMV-NP protein production and purification
Expression plasmids encoding a 6x His tagged version of the LCMV
nucleoprotein (NP) (nucleoprotein sequences from LCMV-Arm and LCMV-CL13
have 100% homology) were a kind gift from D. Pinschewer (University of Basel,
Basel, Switzerland) and originally developed by H. Pircher (University of
Freiberg, Germany) and was used as previously described (Fallet et al., 2016;
Schweier et al., 2019; Sommerstein et al., 2015). Briefly, plasmid was
transformed into Rosetta™ 2(DE3) competent cells (Novagen, Millipore Sigma).
Protein expression was induced with .5M IPTG (Sigma) for 24 hours. Bacteria
were harvested after induction, lysed and sonicated. The soluble fraction was
purified over a HiTrap TALON crude column (GE Healthcare) on a GE
AKTAprime plus FPLC system (GE Healthcare). Purified protein was desalted
using PD-10 columns (GE Healthcare) and concentrated prior to use.

3.2.4 Single cell suspension preparation and LCMV-specific B cell
staining and enrichment.
Single cell suspensions were obtained from spleens by homogenizing
tissues against a 70um cell strainer. Cells were washed through cell strainer and
red blood cells were lysed in ACK lysis buffer (Thermo Fisher Scientific). Cells
were resuspended in MACS buffer (PBS with 1mM EDTA and 2% fetal bovine
62

serum) prior to cell staining or B cell enrichment. To identify LCMV-specific B
cells, purified LCMV-NP was fluorescently labeled with Alexa Fluor 647 or Alexa
Fluor 488 using antibody labeling kits according to manufacturer’s instructions
(Thermo Fisher Scientific). Single cell suspensions were stained with LCMV-NP
for 15 minutes at 37°C in the presence of Fc-block (anti-CD16/32, 24G2, BD) and
washed twice with MACS buffer prior to staining with additional fluorescent
antibody panels. For bulk and single cell RNAseq experiments, B cell enrichment
(negative selection) was performed using mouse pan-B cell isolation kits (Stem
Cell Technologies) according to manufacturer’s instruction except incubation
times were doubled. Following B cell enrichment, LCMV-NP staining was
performed as described above. LCMV-NP-labeled cell suspensions were further
enriched (positive selection) for LCMV-specific B cells by incubating cells with
anti-Cy5/AF647 microbeads (Miltenyi Biotec) followed by purification over LS
columns (Miltenyi Biotec).

3.2.5 Flow cytometry and cell sorting
Single cell suspensions were prepared and stained with fluorescently
labeled LCMV-NP as described above. Cell suspensions were stained at 4°C for
30 minutes for surface protein staining. Intracellular staining was conducted at
room temperature for 1 hour. Antibodies were purchased from Biolegend:
CXCR4 (L276F12), CD83 (Michel-19), CD86 (GL-1), B220 (RA3-6B2), CD19
(1D3), IgD (11-26c.2a), CD138 (281-2), GL7 (GL7), CD38 (90), F4/80 (BM8),
NK1.1 (PK136), IgM (RMM-1), Ki67 (16A8), CD69 (H1.2F3), Steptavidin-BV786;
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BD Biosciences: CXCR4 (2B11), CD83 (Michel-19), CD19, (1D3), CD138 (2812), CD38 (90), CD4 (GK1.5), Blimp1 (5E7), Bcl6 (K112-91), CD31 (MEC 13.3),
CCR6 (140706), Streptavidin BB780; eBioscience (Thermo Fisher Scientific):
GL7 (GL7), CD4 (RM4-5), CD8 (53-6.7), F4/80 (BM8), NK1.1 (PK136); or from
Southern Biotech: Ly6a (D7). Live cells were discriminated by staining with
Live/Dead Aqua (Thermo Fisher Scientific) or Zombie Yellow (Biolegend). Cell
proliferation was measured by injecting mice ip with 3mg of 5-bromo-2’deoxyuridine (BrdU) 2 hours prior to analysis. Fixation of cells for measurement
of BrdU incorporation was done using a FIX & PERM Cell Permeabilization Kit
with adjusted timings and BrdU was detected using an anti-BrdU antibody
(MoBU-1, Thermo Fisher Scientifc). For cell sorting, samples were sorted directly
into lysis buffer (RLT or RLT+, Qiagen) or into 10% FBS cRPMI supplemented
with 25mM HEPES. Flow cytometry data were acquired on a BD LSR II
instrument or BD Symphony A3 instrument. Cell sorting was performed on a BD
FACSAria enclosed within a laminar flow hood. Data were analyzed using
FlowJo software (FlowJo, LLC).

3.2.8 Single cell RNAseq sample preparation
LCMV-specific GC B cells (CD38-GL7+) were sorted from mice infected
with LCMV-Arm or LCMV-CL13 at day 15 post-infection. Splenocytes from 5
mice per infection were pooled, enriched for LCMV-specific B cell and stained
with surface antibodies as previously described. Samples were gated as LCMVLCMV-SPECIFICIgD-B220+Dump- prior to GC B cell gates. Dump stain included
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CD4, CD8, NK1.1, and F4/80. Cells were sorted for yield then for purity. Samples
were counted using a Countess II Automated Cell Counter (Thermo Fisher
Scientific) prior to library preparation. For library preparation, 5000 cells from
each sample were loaded into a Chromium Controller (10x Genomics),
emulsions were created, and libraries were constructed according to the
manufacturer’s recommend protocols for the Chromium Single Cell 3’ v2 kit (10x
Genomics). Samples were pooled and quantified using a KAPA Library
Quantification Kit (Kapa Biosystems) prior to sequencing on an Illumina NextSeq
550 instrument (150 cycle, high output flow cell).

3.2.9 Single cell RNAseq data processing and analysis
BCL files from sequences samples were demultiplexed, aligned to the
mouse mm10 genome, filtered, and UMI counted using Cell Ranger Software
v2.1 (10x Genomics). 3,270 cells were recovered from LCMV-Arm library with
88,576 mean reads per cell and 2,803 median genes detected per cell. 3,374
cells were recovered from LCMV-CL13 library with 83,259 mean reads per cell
and 2,328 median genes detected per cell. Downstream analysis was performed
using Seurat v2.3.1 (Butler et al., 2018). Complete script reproducing all analyses
from raw data will be available in a github repository upon publication of this data.
Briefly, individual library outputs from the Cell Ranger pipeline were loaded,
filtered to remove cells with > 5% mitochondrial reads and > 6000 unique genes
detected. Filtered data from individual libraries were imputed using SAVER
v0.3.0 (Huang et al., 2018) with default settings. Imputed count matrices were
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used to subsequent analysis in Seurat. Variable genes for each library were
determined by calculating gene-gene correlations using Spearman distance,
scoring gene-gene correlations, and taking the top 1500 highest correlated genes
as described previously (https://hemberg-lab.github.io/scRNA.seq.course,
section 8.3.2 Correlated Expression). Regression was performed to remove
variation due to the number of genes detected or the percent of mitochondrial
reads. Common correlation analysis (CCA) was performed to identify common
sources of variation LCMV-Arm and LCMV-CL13 prior to dataset merging using
the first 12 CCA dimensions. Data was then clustered using the first 12 CCA
dimensions and a resolution parameter of 0.6. Differential gene expression was
conducted using the Wilcoxon rank sum test with a threshold of 0.25.
Single-cell enrichment scores for Figure 3.1 were calculated using the
AddModuleScore function in the Seurat package. Previously published gene sets
were used to calculate LZ and DZ (Victora et al., 2010), PC, MB vs. GC, and MB
vs PC single-cell enrichment scores (Bhattacharya et al., 2007; Shi et al., 2015).
Cluster averaged single cell enrichment scores for each gene signature of
interest were used to define GC zone and differentiation state. Cell cycle scores
were calculated using the CellCycleScoring function in the Seurat package using
previously defined gene signatures for each cell cycle stage (Tirosh et al., 2016).
GO term enrichment was conducted using Metascape v3.0 (Zhou et al., 2019)
with a minimum overlap of 3, p value cutoff of 0.01, and a minimum enrichment
of 1.5..
66

Pseudotime analysis of LZ GC B cells was conducted using Monocle 2
v2.10.1 (Qiu et al., 2017b, 2017a). CCA dimensions were imported from Seurat
and used for pseudotime calculations. Pseudotime trajectory start was inferred
using cell cycle staging and cluster function. Trajectories were rooted to start in
cluster 4. Single cell enrichment scores for gene sets of interest were calculated
using GSVA (Hänzelmann et al., 2013). Preprocessed, filtered, normalized, and
log-transformed scRNAseq expression data was used as input to GSVA treating
each cell as a unique sample. A Gaussian distribution was used for the GSVA
calculation as input data was previously log-transformed. Single-cell GSVA
scores were plotted as a function of pseudotime to obtain the graphs in Figure
3.2.

3.3 Results
3.3.1 scRNAseq reveals germinal center organization.
The bulk RNA sequencing data presented in chapter 2 suggested
divergent fate decisions in LCMV-specific GC B cells responding to acute and
chronic infection including an enrichment in signatures of PC and MB cells in the
GC population in chronic infection. To examine the GC reaction with more
precision and to begin to dissect the specific steps in the GC impacted by chronic
infection, we sorted LCMV-specific GC B cells at day 15 pi from acute and
chronic infection and performed droplet-based single cell RNA sequencing
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(scRNAseq). In total, we analyzed 3270 and 3374 LCMV-specific GC B cells
from GCs of acute and chronic infection, respectively, and clustered initially
without consideration of infection type. Unsupervised clustering identified seven
populations of LCMV-specific GC B cells that clustered according to unique
transcriptional and functional profiles (Figure 3.1A and 3.2A-B). We next sought
to place the clusters identified within the known organization of the GC, in
particular the LZ and DZ. To identify the LZ and DZ, single-cell enrichment
scores were calculated for each cell using previously published genesets (Victora
et al., 2010) for the LZ and DZ GC B cell program (Figure 3.1B and 3.2C). Using
this approach, we identified enrichment of the LZ gene program in clusters 2, 4, 5
and 6 and enrichment of the DZ gene program in clusters 0, 1, and 3. We next
sought to determine if we could identify the output of the GC reaction; PC and
MB. Calculation of single-cell enrichment scores for previously published PC and
MB genesets (Bhattacharya et al., 2007; Shi et al., 2015) identified enrichment of
the MB gene program in cluster 5 and of the PC gene program in cluster 6
(Figure 3.1C and 3.2D). Enrichment of the PC and MB transcriptional programs
occurred within clusters enriched for the LZ program supporting previously
published observations (Ise et al., 2018; Kräutler et al., 2017; Laidlaw et al.,
2017; Suan et al., 2017a) that the decision to undergo terminal differentiation and
exit the GC occurs within the LZ.
Given the importance of cell proliferation in the germinal center reaction,
we next sought to understand the role of the cell cycle in driving clustering of
LCMV-specific GC B cells (Gitlin et al., 2014, 2015; Mcheyzer-Williams et al.,
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2015). Consistent with cell cycle biology as a major driver of the GC reaction we
observed restriction of active proliferation and enrichment for the S phase and
G2/M phase of the cell cycle to clusters belonging to the DZ (clusters 0, 1, and 3)
(Figure 3.1D). In fact, the majority of the heterogeneity observed within the DZ
clusters was driven by differences in cell cycle stage with cluster 0 enriched for
cells in the G2/M phase, cluster 1 enriched for cells in the S phase, and cluster 3
containing a mixture of cells from all three phases of the cell cycle (3.2E). In
contrast, the majority of cells in clusters 4, 5, and 6 were in G1, indicating that
these cells had exited from active division. These data were consistent with
previous studies (Dominguez-Sola et al., 2012; Finkin et al., 2019; Gitlin et al.,
2015) identifying regulation of cell cycle entry as critical for the GC reaction.
Consistent with the calculated single-cell enrichment scores in Figure 3.1B-D,
we observed cluster- and zone-restricted expression of individual genes central
to the LZ (Cd83, Cd86) or the DZ programs (Mki67, Cxcr4) (Figure 3.1E)
(Victora et al., 2010, 2012). Notably, despite being in cell cycle, clusters 2 and 3
enriched for the LZ and DZ signatures, respectively. These data combined with
the cell cycle analysis in Figure 3.1D suggested that cells in cluster 2 were
leaving the LZ, initiating cell cycle and entering the DZ whereas cells in cluster 3
were leaving cell cycle and exiting the DZ back to the LZ. Cells in cluster 4
enriched for genes related to antigen processing and presentation via MHCII
(Cd74 and H2-DMa) and B cell survival and signaling genes (Cd79b and
Tnfrsf13c) suggesting that cells in this cluster are interacting with Tfh and/or
FDCs. In addition to enriching for antigen processing and presentation via MHCII,
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cluster 5 enriched for genes involved in T cell trafficking (Figure 3.2B). Notably,
cluster 6 was defined by the high expression of the PC immunoglobulin secretory
factor Jchain as well as genes related to protein folding, protein localization to the
ER, and response to ER stress. Other key GC B cell genes such as Gpr183,
Foxo1, Il21r, S1pr1, and S1pr2 were expressed in the expected LZ and/or DZ
clusters (Figure 3.1E). Thus, single cell analysis identified LCMV-specific GC B
cells within and transitioning between the LZ and DZ phases of the GC reaction
and also identified clusters with transcriptional signatures consistent with antigen
presentation where GC B cells may interact with APC and also with other known
GC biology such as commitment to PC differentiation (Figure 3.1F).
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Figure 3.1

Figure 3.1: scRNAseq reveals germinal center organization.
(A) tSNE plot of unbiased clustering of LCMV-specific GC B cells at day 15 pi.
(B) tSNE plot depicting single-cell light zone or dark zone geneset enrichment.
(C) tSNE plot depicting single-cell MB or PC geneset enrichment. (D) tSNE plot
depicting cell cycle stage enrichment scores for each cell. (E) Plots showing
expression of selected genes important for GC B cell biology. (F) tSNE plot
depicting cluster identification and cluster annotation of LCMV-specific GC B
cells determined using unbiased clustering.

71

Figure 3.2

Figure 3.2: Unsupervised clustering of LCMV-specific GC B cells identifies
clusters with unique biology and known GC B cell function.
(A) Heatmap of LCMV-specific GC B cell cluster-defining genes. Heatmap
depicts top 10 most differentially expressed genes per cluster. (B) Top enriched
GO terms for each identified cluster in LCMV-specific GC B cells scRNAseq
data. (C) Averaged single-cell enrichment scores for the LZ and DZ gene
signatures in each cluster. (D) Averaged single-cell enrichment scores for genes
upregulated in PC, genes upregulated in MB versus GC B cells, and gene
upregulated in MB vs PC for each cluster. (E) Frequency of cells in each cluster
in the indicated cell cycle stage.
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3.3.2 Chronic infection promotes terminal B cell differentiation and
GC exit.
The single cell analysis of LCMV-specific GC B cells above identified cells
in the LZ and DZ phases, as well as cells in transition between these two phases,
and GC B cells undergoing differentiation towards PC or MB. These data provide
increased resolution into the single cell transcriptional coordination of GC B cell
responses. To understand how chronic infection alters GC B cell fate decisions,
we next investigated how LCMV-specific GC B cells in acute and chronic LCMV
infection differ with respect to the clusters of GC B cell biology defined in the
scRNA-seq data. To this end, we first determined the frequency of LCMV-specific
GC B cells from acute and chronic infection within each cluster. Both acute and
chronic infection had similar frequencies of LCMV-specific GC B cells in the DZ
clusters (Figure 3.3A). However, chronic infection resulted in increased
frequency of LCMV-specific GC B cells in the pre-PC (cluster 6) and pre-MB
(cluster 5) clusters by 6.6-fold and 1.8-fold, respectively. Conversely, chronic
infection diminished the frequency of cells in transition from LZ to DZ (cluster 2)
by 1.4-fold. Thus, chronic infection promoted accumulation of virus-specific GC B
cells in the pre-PC and pre-MB fates and depletion of cells re-entering the cell
cycle and the DZ.
GC B cell differentiation reflects a stepwise, circular, differentiation
scheme with distinct biology including rapid proliferation and somatic
hypermutation in the DZ, exit from cell cycle and testing of BCR, and then key
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decision points in the LZ to initiate either DZ reentry or begin a PC or MB
differentiation path. To begin to understand how chronic infection might alter
these biological events and decision points in the GC, we next applied
pseudotime analysis to infer differentiation trajectories and cluster
interconnectedness (Qiu et al., 2017b, 2017a). Pseudotime analysis of LZ
clusters 2, 4, 5, and 6, revealed two major branch points (Figures 3.3B and
3.4A). The first branch point was between cluster 4 and 2 where GC B cells are
interacting with FDC and Tfh (cluster 4), or GC B cells are returning to the DZ
(cluster 2), and clusters 5 and 6 where cells are undergoing differentiation into
MB and PC, respectively. LCMV-specific GC B cells in chronic infection favored
the branch toward the pre-MB and pre-PC fates whereas cells in acute infection
favored the DZ re-entry branch (Figure 3.3B). This pseudotime analysis is
consistent with the strong shift in cluster frequency seen in Figure 3.3A with
LCMV-specific GC B cells from chronic infection highly biased to the pre-PC and
pre-MB cell fates. The second branch point occurred in the DZ re-entry cluster
also separated cells by infection. These data suggest that chronic infection not
only drives terminal differentiation of GC B cells within the LZ when GC B cells
are interacting with Tfh and FDC, but that chronic infection also alters LZ GC B
cells re-entry to the DZ.
To test these predictions, we treated mice infected with acute LCMV or
chronic LCMV with 5-bromo-2’-deoxyuridine (BrdU) 2 hours prior to analysis
(Figure 3.3C). We reasoned that because BrdU is only incorporated into actively
dividing cells, the short BrdU labeling prior to analysis would provide a defined
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window into the cellular output of the GC reaction at day 15 pi. BrdU
incorporation was 2-fold lower in LCMV-NP-specific B cells in chronic infection
(Figure 3.3C) indicating less proliferation overall. Of the LCMV-NP-specific B
cells that proliferated during the 2hr labeling window (BrdU+), GC B cell
frequencies were decreased whereas MB and PC frequencies were increased in
chronic infection compared to acute infection (Figure 3.3D). Although some of
this MB and PC BrdU incorporation could be occurring outside the GC in this
analysis, these data when combined with our scRNAseq pseudotime analysis
further support the notion that chronic infection skews LCMV-NP-specific GC B
cells towards terminal differentiation and GC exit rather than DZ reentry.
GC B cell differentiation and positive selection involves integration of
multiple extracellular signals (Mesin et al., 2016; Shlomchik et al., 2019). Of the
pathways that can influence GC B cell fate decisions, e.g. antigen, inflammatory
cues, and signals from T follicular helper cells (Tfh), several were implicated in
the scRNA-seq and bulk RNA-seq above. Therefore, we used pseudotime
projection of transcriptional signals across the phases of GC progression in acute
versus chronic infection to examine CD40 (i.e. from Tfh), inflammatory signaling,
BCR and activation of c-Myc and MTOR which occurs after a BCR positive
selection signal is received (Dominguez-Sola et al., 2012; Ersching et al., 2017;
Finkin et al., 2019; Luo et al., 2018).
We first analyzed signals derived from Tfh cell help given that chronic
LCMV infection leads to an abundance of Tfh (Crawford et al., 2014; Fahey et al.,
2011; Greczmiel et al., 2017; Vella et al., 2017). Tfh cell help to GC B cells
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comes not only through pMHCII:TCR interaction (Crotty, 2015; Schwickert et al.,
2011) but also through critical costimulatory interactions via CD40-CD40L (Ise et
al., 2018; Kawabe et al., 1994; Watanabe et al., 2017) that drive GC B cell
survival and entry into the DZ. Both acute and chronic infection upregulated
expression of genes related to the response to CD40 signaling within LZ GC B
cells of cluster 4 and along the branch leading to PC and MB differentiation
(Figure 3.3E). This result is consistent with previous observations that Tfh cells
are abundant during both acute and chronic infection (Crawford et al., 2014;
Fahey et al., 2011; Greczmiel et al., 2017; Vella et al., 2017) and that CD40
agonism can drive terminal PC differentiation in vitro (Erickson et al., 2002; Foy*
et al., 1996). However, although the enrichment was similar between infections,
the pattern of this CD40 “help signal” was distinct. Enrichment of CD40 signaling
genes in acute infection increased early in the pseudotime trajectory. In chronic
infection, this CD40 signature was instead predominantly found in the latter parts
of the pseudotime trajectory where the pre-MB and pre-PC features where
present. Thus, despite the abundance of Tfh cells in chronic infection, these data
suggest that Tfh help might not be available during the same steps in GC B cell
differentiation. Whether these differences are due to B cell intrinsic features,
alterations in Tfh homing and migration, GC architectural differences, or help
signal delivery will require future examination.
Following interaction with Tfh cells and positive selection in the GC, B
cells upregulate Myc targets, activate MTOR, and reenter cell cycle (DominguezSola et al., 2012; Ersching et al., 2017; Finkin et al., 2019; Luo et al., 2018).
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Because LCMV-specific GC B cells in acute versus chronic infection appeared to
differ at the DZ re-entry step (Figure 3.3B) and because CD40 signals were
diminished in the T cell and FDC interaction cluster during chronic infection, we
hypothesized that induction of MTOR or Myc target genes would be reduced in
chronic infection. However, Myc target genes and MTORC1 signaling were
enriched in LZ GC B cells returning to the DZ during both acute and chronic
infection, and neither pathway was differently associated with the observed
branching between the two infections (Figure 3.3F and 3.4B). These
observations suggest that once an effective BCR and help signal was received,
engagement of the downstream metabolic transcriptional program proceeded
similarly in acute versus chronic infection. It remains possible that nontranscriptional control of metabolism checkpoints has a role, but the lack of
differential enrichment of the Myc and MTORC1 signaling genesets suggested
that transcriptional control of these pathways was not altered, despite differential
DZ reentry.
We next assessed transcriptional evidence of signaling BCR during
chronic infection. Given the abundance and chronicity of antigen during chronic
infection, we hypothesized that stronger BCR signaling in GC B cells would
perturb GC B cell cluster dynamics. In acute infection, signatures of BCR
signaling were enriched in GC B cells re-entering the DZ but not as cells exited
the GC reaction (Figure 3.3G) supporting a role for BCR signaling in efficient DZ
re-entry. However, despite substantially more antigen in chronic infection, the
transcriptional signature of BCR signaling during chronic infection was actually
77

reduced in LCMV-specific GC B cells compared to cells responding to acute
infection (Figure 3.3F). Although the LCMV-specific GC B cells that did re-enter
the DZ during chronic infection did display modest enrichment for BCR signaling,
the enrichment of this signature was both lower in magnitude and temporally
delayed in pseudotime space compared to acute infection. These data suggested
that BCR signaling in LCMV-specific GC B cells during chronic infection is
attenuated, perhaps early in the process of testing BCR after emerging from the
DZ and entering cluster 4. Expression of cell surface inhibitory receptors or
intracellular signaling attenuators did not provide an obvious explanation for
attenuated BCR signaling during chronic infection (Figure 3.5A). Instead, we
observed downregulation of many BCR pathway genes in LCMV-specific GC B
cells within cluster 4 during chronic infection (Figure 3.5B). These results
suggest that BCR signaling rather than its endocytic functions (i.e. because the
ability to elicit Tfh help and receive CD40 signals were intact) were impaired in
LCMV-specific B cells during chronic infection.

Chronic infections can not only impact antibody responses to the
persisting infection itself, but also bystander antigen such as vaccines suggesting
a role for chronic inflammation in addition to persisting antigen (McKittrick et al.,
2013; Shive et al., 2018; Stelekati and Wherry, 2012; Wiedmann et al., 2000)
Thus, we next sought to determine the role of persistent inflammation in altering
GC B cell differentiation. Genes related to inflammatory responses, interferon-a,
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and interferon-g were strongly enriched in LCMV-specific GC B cells undergoing
differentiation into PC and MB (Figure 3.3F and 3.4D-E). Moreover, even in the
pseudotime branch of LZ GC B cells returning to the DZ that was biased to
chronic infection, inflammatory signaling gene transcription was also enriched.
Thus, persistent inflammatory signaling during chronic infection was strongly
associated with the skewed differentiation of LCMV-specific GC B cell towards
the PC and MB and early GC exit. Together, these data suggest that altered
sensing of antigen and persistent inflammation are associated with altered B cell
differentiation during chronic infection promoting early GC exit and altered
reentry into the DZ. In particular, these data implicate a key step in the transition
from DZ to LZ (i.e. cluster 4) where BCR signaling attenuation may be important
and a role for signals from chronic inflammation throughout the cluster 4 à
cluster 2 reentry or cluster 4 à GC exit program, but especially as GC B cells
commit to the PC or MB fate.
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Figure 3.3

Figure 3.3: Chronic infection promotes terminal B cell differentiation and
GC exit.
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(A) tSNE and bar plots depicting cluster occupancy of LCMV-specific GC B cells
from LCMV-Arm (Acute) and LCMV-CL13 (Chronic) infected mice at day 15 postinfection. (B) Pseudotime analysis (Monocle 2) of light zone GC B cell
populations identified using scRNAseq. Pseudotime constructed using all light
zone GC B cell populations and visualized separated by infection. Pseudotime is
rooted in cluster 4: T cell and FDC interactions. (C) Single-cell GSVA enrichment
scores for Basso CD40 signaling genes UP geneset plotted as a function of
pseudotime. (D) Single-cell GSVA enrichment scores for Hallmark MYC targets
V2 geneset plotted as a function of pseudotime. (E) Single-cell GSVA enrichment
scores for Reactome BCR signaling geneset plotted as a function of pseudotime.
(F) Single-cell GSVA enrichment scores for Hallmark Inflammatory geneset
plotted as a function of pseudotime.
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Figure 3.4

Figure 3.4: Pseudotime analysis identifies GC B cell fate decision points
within the LZ and correlated gene expression signatures.
(A) Pseudotime analysis (Monocle 2) of light zone GC B cell populations
identified using scRNAseq. Pseudotime is rooted in cluster 4: T cell and FDC
interactions. Plots depict pseudotime, cell cycle stage, cluster identity, and
distinct pseudotime states of LCMV-specific LZ GC B cells. (B) Single-cell GSVA
enrichment scores for Hallmark MTORC1 signaling geneset plotted as a function
of pseudotime. (C) Single-cell GSVA enrichment scores for Hallmark PI3KMTOR-AKT signaling geneset plotted as a function of pseudotime. (D) Single-cell
GSVA enrichment scores for Hallmark Response to Interferon Alpha geneset
plotted as a function of pseudotime. (E) Single-cell GSVA enrichment scores for
Hallmark Response to Interferon Gamma geneset plotted as a function of
pseudotime.
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Figure 3.5:

Figure 3.5: BCR signaling pathways are altered in LZ GC B cells during
chronic infection.
(A) Expression of B cell inhibitory receptors and phosphatases in LCMV-specific
B cells in cluster 4: T cell FDC interactions. (B) Expression of genes downstream
of the BCR in LCMV-specific B cells in cluster 4: T cell FDC interactions.
***p<0.001 Wilcoxon Rank Sum Test
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3.3.3 Chronic inflammation and altered antigen sensing in GC
responses during chronic viral infection.
Pseudotime analysis combined with GSVA identified decreased CD40
signaling, impaired BCR signaling, and increased inflammatory signaling
associated with terminal differentiation and GC exit of GC B cells during chronic
infection. Given the known role for CD40 in regulating GC B cell DZ reentry and
positive selection (Gitlin et al., 2014; Shulman et al., 2013; Victora et al., 2010)
and that we observed diminished CD40 signals in GC B cells interacting with Tfh
or FDC in the LZ during chronic infection, we hypothesized that agonism of the
CD40 pathway during chronic infection would prevent PC differentiation and
promote continued participation in the GC reaction. To address this question, we
treated mice infected with either acute or chronic LCMV with the blocking
antibody anti-CD40L (MR1) or the agonizing antibody anti-CD40 (FGK45) at day
13 pi and analyzed the response at day 16 pi. Agonism of the CD40 pathway
during acute infection led to GC B cell expansion whereas CD40L blockade led
to dissolution of the GC response and a corresponding increase in PC frequency
(Figure 3.6A). In contrast to acute infection, and in disagreement with our
hypothesis, agonism of the CD40 pathway during chronic infection had no effect
on LCMV-specific GC B cell, PC, or MB responses (Figure 3.6B). However, we
did observe a trend towards MB differentiation during CD40L blockade. Impaired
response to CD40 pathway manipulation during chronic infection was
unexpected given the transcriptional evidence of diminished but present CD40
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signals in our scRNAseq analysis. Whether the lack of response to CD40
pathway modulation in chronic infection was due to suboptimal dosing (Beatty et
al., 2011), impaired antibody Fc-mediated functions during chronic infection
(Wieland et al., 2015), or functional inhibition of this signaling axis will require
further investigation. Together, these data suggest that chronic infection impairs
GC B cell responsiveness to CD40 signals.
In addition to diminished CD40 signaling, we also observed transcriptional
evidence of impaired BCR signaling in GC B cells during chronic infection.
Therefore, we next interrogated the impact of BCR signals on GC B cell
differentiation. BCR signaling is critical for the maintenance of the GC response
and blockade of BCR signaling using the BTK inhibitor has been previously used
to inhibit GC B cell responses during acute LCMV infection (Mueller et al., 2015).
Because we observed enrichment of BCR signaling in GC B cells undergoing DZ
reentry during acute infection (Figure 3.3G) we hypothesized that inhibiting BCR
signaling during acute infection would lead to GC B cell exit and differentiation. In
contrast, because the BCR signaling transcriptional network was diminished in
chronic infection, we predicted that BCR inhibition would have a smaller impact in
LCMV-CL13 infection. To test these predictions, we administered the BCRinhibiting drug ibrutinib to mice infected with acute or chronic LCMV starting at d3
as previously described (Figure 3.7A) (Mueller et al., 2015; Yang et al., 2016).
Indeed, BCR inhibition during acute infection led to decreased LCMV-specific GC
B cell responses and increased MB frequencies, consistent with the known role
of BCR signaling in GC re-entry (Figure 3.7B). In contrast and as predicted,
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inhibition of BCR during chronic infection had no impact of LCMV-specific B cell
differentiation. These results were consistent with our scRNAseq analysis in
Figure 3.3G and suggest that skewing of GC B cell differentiation toward PC and
MB differentiation and away from DZ reentry during chronic infection is
associated with BCR signaling so attenuated that the negative effects on the GC
response cannot be furthered by molecular BCR inhibition with ibrutinib.
The data above suggested that chronic infection disrupts BCR signaling
and the ability to respond to T cell help. Because IFN-I has been implicated in
chronic infection as the driver of pre-GC disruption of B cell responses (Fallet et
al., 2016; Moseman et al., 2016; Sammicheli et al., 2016), we next sought to
understand whether chronic inflammation is a driver of altered fate decisions
after the GC has formed. In support of this, one of the strongest differential
signatures in our bulk RNAseq in chapter 2 (Figure 2.7D) was response to
interferon and inflammatory signaling. We then assessed these pathways in our
scRNA-seq data and also identified response to interferon and inflammatory
signals as one of the strongest differential signals in GC B cells responding to
acute versus chronic infection (Figure 3.3H). Of note, it has been previously
understood that GC B cells are nonresponsive to IFN-I signals owing to their
overall low expression of Ifnar1 and Ifnar2 (immgen.org, (Heng et al., 2008)).
However, when individual GC clusters were examined, we observed specific,
focal expression of Ifnar1 and Ifnar2 in the testing cluster 4, where GC B cells are
interacting with Tfh and FDC (Figure 3.8A). This observation suggested that GC
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B cells may still be sensitive to IFN signaling, specifically at a key step in the GC
where signals are being integrated for GC B cell fate decisions.
Given these scRNA-seq data and previous studies on the effects of IFN-I
on pre-GC B cell responses, we directly interrogated the role of IFN-I on GC B
cell fate decisions. To do this, we first tested whether disruption of IFN signaling
only in B cells during chronic infection would alter the LCMV-NP-specific GC B
cell response. Genetic ablation of IFN signaling only in B cells using
CD19CrexIFNARflox/flox mice during chronic infection resulted in a 1.6-fold reduction
in the frequency of LCMV-specific PC but did not alter the GC B cell or MB
compartments (Figure 3.8B). Because this reduction in PC frequencies could be
due to the impact of type I interferon before the GC response, we next performed
systemic antibody blockade of type I interferon signaling in acute and chronic
infection as described (Wilson et al., 2013a) starting at d13 pi when GC formation
had already been initiated. Systemic blockade of type I interferon signaling
beginning at d13 pi did not impact the overall magnitude of the LCMV-NPspecific response (Figure 3.8C) nor did it change LCMV-NP-specific PC, GC B
cell or MB frequencies during either acute or chronic infection (Figure 3.8D).
These results support the idea that although Ifnar1 and Ifnar2 are expressed in
LCMV-NP-specific GC B cells, the major impact of type I interferon during
chronic infection is to promote PC differentiation prior to the formation of the GC
response. Moreover, these data suggested that the IFN and inflammatory
signature observed in GC B cells is due to a residual transcriptional effect of IFN87

I signaling prior to GC formation, signals from IFN-g, and/or signals from other
inflammatory pathways.
We next wanted to test the inflammatory environment separately from the
effects of chronic antigen. To do this, we infected mice with LCMV Arm or Cl13
and then injected the mice with one dose of recombinant phycoerythrin (1x PE;
Figure 3.8D). If inflammation was playing a driving role in skewed GC B cell fate
decisions during chronic infection, we predicted that the PE responses in LCMVCL13-infected mice would be similarly skewed. Although the magnitude of the
PE-specific B cell response was similar between Arm and clone 13 mice (Figure
3.8F), the differentiation of PE-specific B cell responses in mice with chronic
infection was, indeed, altered (Figure 3.8G-H). Specifically, PE-specific PC were
increased during chronic infection and the GC B cell response was reduced. The
ability of chronic infection to skew responses to a one-time dose of PE supported
a dominant role for environment and/or inflammation in the skewing of B cell
responses during chronic infection.
We next wondered whether the altered B cell responses to PE during
CL13 infection indicated that inflammation alone causes altered GC B cell fate
decisions or whether some alterations could also be caused by chronic antigen
as well. We therefore designed a variation of the PE immunization experiment
but, instead of a single PE dose, we gave repeated immunizations to expose B
cells to antigen “chronically” for 2 weeks (Figure 3.8D). In this model, if chronic
antigen played an additive role, we would expect that chronic PE administration
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in CL13 infection would further skew the PE-specific response to look like those
observed against LCMV-NP. Repeated administration of PE increased the
magnitude of the total PE-specific B cell response in both acute and chronic
LCMV infection (Figure 3.8E). However, repeated immunization with PE did not
impact PC frequencies in either acute or chronic infection suggesting that antigen
dose (at least within the range tested) did not play a major role in determining the
PC fate (Figure 3.8G-H). Repeated immunization did reduce the MB
compartment in both Arm and clone 13 infection, although the effect was less
dramatic in chronic infection (Figure 3.8H). In contrast to PC and MB fates,
repeated immunization had a dramatically different impact on GC B cells in acute
versus chronic infection. In acute LCMV, repeated immunization doubled the
magnitude of the PE-specific GC response (Figure 3.8G-H). In contrast,
repeated antigen exposure in the setting of chronic infection resulted in a nonsignificant increase in the PE-specific GC response (Figure 3.8G-H). Taken
together, these data suggest that sustained antigen is better able to induce DZ
re-entry in acute infection than in chronic infection and are consistent with the
scRNA-seq data on compromised BCR signaling in GC B cells during chronic
infection. However, with an increase in total PE-specific B cells and very little
change in the PC, MB, and GC fates when PE was given 5 times in CL13
infection, it should be noted that the increase was driven instead by a CD38-GL7CD138- B cell response, an uncharacterized subset that may contain ageassociated B cells (Rubtsova et al., 2015) or other B cell populations. Taken
together, these data suggest that persistent inflammation and/or environmental
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changes, rather than chronic antigen, is a dominant driver of increased terminal
differentiation of GC B cells observed in chronic infection.
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Figure 3.6

Figure 3.6: LCMV-specific B cell differentiation is not sensitive to CD40
pathway modulation during chronic infection.
CD40 pathway was manipulated in mice with either acute or chronic LCMV by
treatment of mice with anti-CD40L (MR1, 200ug/mouse ip) or anti-CD40 (FGK45,
25ug/mouse ip) at d14 post infection followed by analysis at day 15. (A)
Frequency of LCMV-specific PC, GC B cells, and MB in LCMV-Arm (acute)
infected mice at d16 pi. (B) Frequency of LCMV-specific PC, GC B cells, and MB
in LCMV-CL13 (chronic) infected mice at d16 pi. Data points in A and B show
mean ± SEM. *p<0.05, **p<0.01, Student’s t-test.
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Figure 3.7

Figure 3.7: Inhibition of BCR signaling does not impact LCMV-specific B
cell responses.
(A) Experimental timeline. Mice were infected with either acute or chronic LCMV.
Starting at d3 pi mice were treated either with vehicle or vehicle + 250ug Ibrutinib
twice daily on days 3, 6, 9, and 12 pi before analysis on day 15 pi. (B) Frequency
of LCMV-specific PC, GC B cells, and MB in LCMV-CL13 (chronic) infected mice
at d15 pi as treated in A. Data points in B show mean ± SEM. *p<0.05, **p<0.01,
Student’s t-test.
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Figure 3.8
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Figure 3.8: Chronic antigen and inflammation impair the germinal center
response during chronic viral infection.
(A) tSNE plot depicting expression of Ifnar1 and Ifnar2 in day 15 pi LCMVspecific GC B cell scRNAseq data. (B) Frequency of splenic LCMV-specific
plasma cells, germinal center B cells, and memory B cells in wildtype or IFNARf/f
infected mice at d15 post-infection. (C) Frequency of LCMV-specific plasma
cells, germinal center B cells, and memory B cells in groups depicted in A. (D)
Experimental setup for testing the role of inflammation in panels E and F. Mice
were split into four groups and infected with either LCMV-Arm or LCMV-CL13.
Within these groups, mice either received one 200ug ip immunization of
recombinant PE or 5x immunizations with 200ug ip every three days postinfection (0, 3, 6, 9, 12). Mice were analyzed at d15 post infection. (E) Frequency
of PE-specific B cells in mice in each group depicted in D. (F) Frequency of PEspecific plasma cells, germinal center B cells, and memory B cells in groups
depicted in D. Each plot depicts mean ± SEM with 3-5 mice per group from one
of two representative experiments. *p<0.05, **p<0.01, ***p<0.001, Student’s ttest.
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3.4 Discussion
Balancing the decision to remain within the GC and continue undergoing
affinity maturation or to exit the GC as an antibody-secreting PC or MB is critical
for the development of effective humoral immune responses (Cyster and Allen,
2019; Mesin et al., 2016; Shlomchik et al., 2019). Regulation of this checkpoint
involves translating BCR signals, antigen-presentation, and Tfh cell help into
either PC or MB differentiation or DZ re-entry as discussed in chapter 1.2.4. The
studies completed in chapter 2 of this thesis found that chronic viral infection
alters virus-specific B cell responses by skewing B cell differentiation away from
the GC fate and towards the PC and MB fates. Yet, despite skewed B cell
differentiation during chronic infection where and how chronic infection impacts
the GC B cell response are unclear. Given that persistent antigen is a feature of
chronic viral infection, it is likely that chronic infection may disrupt GC B cell
decision making.
The studies outline in this chapter address these questions. Interrogation
of the GC B cell response to acute and chronic viral infection at single-cell
resolution identified a key GC B cell checkpoint in the LZ that is dysregulated
during chronic viral infection. Rather than undergoing positive selection and DZ
reentry, GC B cells during chronic infection favor PC and MB differentiation and
GC exit. Inefficient DZ reentry during chronic infection was associated with
diminished CD40 signaling, attenuated BCR signaling, and increased
inflammatory gene signatures.
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The finding that BCR signaling was attenuated in chronic infection was
surprising. Instead, we had hypothesized that chronic antigen would promote
strong BCR signals leading to PC differentiation consistent with the two-signal
BCR affinity model of differentiation outline in chapter 1. However, this result is
consistent with other settings of B cell chronic antigen exposure such as
autoimmunity where B cells undergo a state of functional unresponsiveness
known as B cell anergy (Yarkoni et al., 2010). The distinction between anergy
and BCR attenuation during chronic viral infection (like the distinction between
anergy and exhaustion in CD8 T cells) (Schietinger and Greenberg, 2014) is not
made clearer by these data.
To dissect the relative influence of chronic antigen and chronic
inflammation, we modulated antigen loads, CD40 signals, and inflammation in
the LCMV model system. Our studies identified a dominant role for persistent
inflammation over chronic antigen exposure in shaping altered GC B cell
differentiation during chronic infection. Interrogation of type I interferon signaling
did not seem to impact virus-specific GC B cell responses following the formation
of the GC, suggesting that the impact of type I interferon signaling on humoral
immunity is in shaping the extrafollicular phase of the humoral immune response
as has been previously shown but that these pathways do not robustly modulate
the GC response. Taken together, our findings have important implications for
vaccination. First, it may explain why individuals with chronic inflammation such
as the aged or those with pre-existing chronic infections have poor response to
vaccination (McKittrick et al., 2013; Shive et al., 2018; Wiedmann et al., 2000).
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Second, while our studies did not identify a causal soluble inflammatory mediator
as a driver of altered GC B cell differentiation, such a molecule could provide a
therapeutic target for improved humoral immunity during chronic viral infection or
other settings of chronic inflammation.
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CHAPTER 4: Concluding Remarks and Future Directions
4.1 Overview of results
Effective humoral immune responses to acute infection and immunization
are defined by the induction of high-affinity antibodies generated as the result of
B cell activation and differentiation (Cyster and Allen, 2019; Mesin et al., 2016;
Plotkin, 2008). In contrast to acute infection or immunization, humoral immune
responses during chronic infections are often dysregulated. Chronic infections,
like HIV (Gray et al., 2007; Lane et al., 1983; Milito et al., 2004; Moir and Fauci,
2017), HCV (Bjøro et al., 1994; Cashman et al., 2014; Logvinoff et al., 2004;
Racanelli et al., 2006), and chronic LCMV (Battegay et al., 1993; Hunziker et al.,
2003; Oldstone and Dixon, 1969), are characterized by increased antibody
quantity but decreased antibody quality. Additionally, individuals with pre-existing
chronic infections have poorer responses to vaccination (McKittrick et al., 2013;
Shive et al., 2018; Wiedmann et al., 2000). Given the critical role for the GC in
regulating both antibody quantity and quality, these defects suggest a central role
for alterations in GC biology during chronic infection. Yet, the exact impact of
chronic infection on the formation and maintenance of the GC response remains
poorly understood. Understanding how chronic viral infections alter the normal
humoral immune response can therefore (i) define targets to modulate defective
humoral immunity and (ii) give mechanistic insight into the signals that govern the
B cell response. The studies completed in this thesis identify a key LZ checkpoint
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and underlying cellular and molecular mechanisms that lead to dysregulated
humoral immunity in chronic infection.
In chapter 2 of this thesis, the impact of chronic infection on the
development of antigen-specific humoral immunity was investigated. Through the
use of novel recombinant protein reagents (Fallet et al., 2016; Schweier et al.,
2019; Sommerstein et al., 2015), virus-specific B cell responses were found to be
diminished in magnitude and altered in phenotype when compared to B cells
specific for the same viral protein responding to acute infection. Chronic infection
skewed virus-specific GC B cell responses towards terminal PC and MB
differentiation and away from continued participation in the GC response.
Skewing toward the PC and MB fates was associated with decreased serum
antibody avidity and fewer accumulated BCR mutations. Transcriptional profiling
of LCMV-specific B cells during acute and chronic infection identified early
dysregulation of the LCMV-specific GC B cell response resulting in induction of
the PC and MB gene signatures during chronic infection. Thus, chronic infection
promotes PC and MB differentiation at the expense of the GC fate and this
skewing correlates with delayed development of high-affinity antibodies.
In chapter 3 of this thesis, the mechanisms underlying skewed GC B cell
differentiation during chronic infection were investigated. Interrogation of the
LCMV-specific GC B cell response using scRNAseq identified a key LZ
checkpoint that is dysregulated during chronic infection. Rather than undergoing
DZ re-entry and continued participation in affinity maturation, GC B cells instead
were biased towards GC exit and differentiation into the PC and MB fates. Early
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GC B cell exit during chronic infection occurred in the LZ when GC B cells are
interacting with Tfh or FDC. GC B cell exit and differentiation was associated with
intact but diminished CD40 signaling, attenuated BCR signaling, and increased
inflammatory signaling but not altered induction of the Myc or MTOR gene
signatures. Modulation of the CD40 pathway and BCR signaling during chronic
infection did not restore altered GC B cell differentiation. Type I interferon was
found to have a role in promoting altered B cell differentiation during chronic
infection but likely acts before the initiation of the GC response. Thus, the broad
inflammatory milieu of chronic infection was found to have a dominate role in
stunting GC B cell responses suggesting that chronic infection induces a broad
state of immunosuppression.
Taken together, chapters 2 and 3 of this thesis not only extend our
understanding of how GC B cell responses are coordinated during chronic
infection, but also provide deeper clarity into molecular programs, including
specific genes and pathways, that are altered by persisting infection. These
studies found that persistent inflammation during chronic infection disrupts a key
DZ re-entry checkpoint in the GC causing skewing of GC B cell differentiation
towards PC and MB differentiation and away from continued participation in the
GC reaction. This skewing away from the GC was associated with decreased
antibody affinity maturation and gives at least one mechanism by which chronic
infection delays development of neutralizing antibody.
As will be discussed below, this work adds to our knowledge of the signals
and contexts driving B cell fate decisions by directly perturbing aspects of the
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system and then interrogating the effects on the GC output. Our observations
suggest that the two-signal model of GC B cell differentiation (antigen and T cell
help) (Shlomchik et al., 2019) can be affected by inflammation and that
inflammation can promote early GC exit even in the setting of abundant antigen
and abundant Tfh. The findings outlined in chapters 2 and 3 also suggest
persistent inflammatory signals, as is observed in individuals with other chronic
infections, may serve as a mechanism for poor vaccine responses in other
contexts (McKittrick et al., 2013; Shive et al., 2018; Wiedmann et al., 2000).

4.2 The role of chronic antigen in the regulation of the humoral
immune responses to chronic infection
The studies in chapters 2 and 3 identified the problem – that chronic
infection led GC B cells in the LZ to preferentially exit as a terminal PC or MB
cells rather than re-enter the DZ for further affinity mature. The regulation of this
GC B cell checkpoint has been extensively studied in mouse models of hapten
immunization with two model antigens used as immunogens: hen egg lysozyme
and the (4-hydroxy-3-nitrophenyl)acetyl (NP) hapten (Gitlin et al., 2014; Ise et al.,
2018; Phan et al., 2006). The primary decision model derived from these
immunization experiments is the BCR-based affinity model discussed in chapter
1.2.3, where regulation of the decision to undergo positive selection and DZ
reentry or differentiation within the GC depends critically on translating BCR
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affinity into 1) BCR signals and 2) Tfh help (Cyster and Allen, 2019; Mesin et al.,
2016; Shlomchik et al., 2019). This immunization model defined a “Goldilocks”
threshold of “just right” signals that promote positive selection and DZ re-entry,
where affinity maturation can continue. The decision to instead exit the GC
reaction as a PC or MB typically occurs when the signal is slightly above the
Goldilocks range (PC differentiation) or slightly below (MB differentiation).
In contrast to immunization, the kinetics of antigen exposure during
infection is not a bolus. In acute infection, antigen logarithmically rises to an
eventual peak followed by a decline, and in chronic infection, antigen also rises
logarithmically to a peak but then stabilizes at a high level of persisting antigen
available to stimulate B cells. The way that the kinetics of antigen quantity
regulates GC B cell fate decision differently than immunization is not clear. In
acute infection, the BCR-based affinity model of GC fate decisions would predict
that early in infection— as antigen is just beginning to rise but remains below the
DZ re-entry threshold for a given clone—a MB fate for the less competitive clone
would be preferred (Laidlaw et al., 2017; Suan et al., 2017a; Weisel et al., 2016).
Then, as antigen becomes more abundant, the affinity requirements for antigen
encounter and capture may be less competitive, allowing for more GC B cells to
achieve sufficient signaling that exceeds the DZ-reentry threshold and leading to
differentiation into the PC fate (Ise et al., 2018; Kräutler et al., 2017; Weisel et al.,
2016). Then, as virus is controlled and antigen decreases, the MB fate may again
be preferred. Our data during LCMV-Arm acute infection were consistent with
this model and showed that MB cell differentiation is favored early (d10) during
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the GC response but also later as GC B cell responses are resolved. These
results are consistent with recent studies outlining that the GC response to
immunization favors output of MB early but PC later during the response (Weisel
et al., 2016). At this coarse level, it appears that the differences in antigen
kinetics between immunization and acute infection do not alter the relative GC
differentiation into the PC or MB cell fates, possibly due to the rapid expansion of
available antigen in viral infection that may mimic a bolus delivery of antigen.
In both immunization and acute infection, antigen moves from abundant to
limiting. In contrast, during chronic infections antigen levels can often be
persistently high and therefore potentially non-limiting for the duration of
infection. What happens to GC B cell fate decisions in this setting? A fascinating
feature of B cell biology is that the BCR has two mutually exclusive functions,
signaling and endocytosis of antigen, that translate BCR affinity into downstream
fate decisions (Hou et al., 2006; Shlomchik et al., 2019). In the context of
abundant antigen, both BCR signals and capture of antigen would likely be
increased for all B cells potentially minimizing differences in BCR affinity between
B cell clones. Therefore, based on the BCR-based affinity model it could be
predicted that lower affinity B cells would be more apt to receive sufficient signals
to exit as PC when in limiting antigen environments they would only have
sufficient affinity to be positively selected for more affinity maturation. Likewise,
persistent antigen (Wherry et al., 2003a) and abundant Tfh (Greczmiel et al.,
2017; Vella et al., 2017), as observed during chronic infection, may allow cells to
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be shunted towards a MB fate when an environment of limiting antigen might
otherwise place the B cell below the survival threshold.
It can then be predicted using the BCR-affinity differentiation model that
high and sustained antigen loads during chronic infection would induce strong
BCR signals and favor PC differentiation over the GC B cell or MB fate. Indeed,
this is what was observed in chapter 2. PC differentiation was favored prior to
formation of the GC and through the initial 3 weeks of the immune response.
Only when viral loads begin to be controlled within the spleen (d10-d21) do GC B
cells begin to expand during chronic infection (Wherry et al., 2003a). One
particularly interesting finding is that although, chronic infection promotes PC and
MB differentiation early during the GC response, it isn’t until GC B cell numbers
begin to increase that differences in serum antibody avidity between acute and
chronic infection begin to emerge. Why this occurs is still unclear but it does
suggest that some critical mass of GC B cells has to be achieved for GC B cell
competition and affinity maturation to occur in an efficient manner.
We then used experimental modulation of Tfh signals and BCR signaling
to test how these two signals and the BCR affinity model work in the context of
acute and chronic infection. Consistent with previous studies, agonism of the
CD40 pathway during acute infection—mimicking Tfh help— promoted the GC B
cell fate while diminishing the MB fate (PC responses were unchanged)
(Ersching et al., 2017; Victora et al., 2010). As expected, blocking BCR signaling
had the opposite effect; BCR inhibition diminished the GC response and led to an
increase in MB. For all intents and purposes, virus-specific B cell responses
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during acute infection acted like previously described anti-hapten responses.
However, responses during chronic infection, where Tfh are abundant and
antigen is plentiful (Greczmiel et al., 2017; Vella et al., 2017; Wherry et al.,
2003a), did not behave as expected. It would be predicted based on the BCRaffinity model that increasing CD40 signals would further promote PC
differentiation whereas limiting BCR signaling would promote the GC B cell fate.
In fact, when experimentally modulated, neither inhibition of BCR signaling nor
manipulation of the CD40 pathway impacted GC B cell fate during chronic
infection.
Further interrogation of these pathways using scRNAseq revealed
diminished CD40 signaling and BCR pathway inhibition in GC B cells during
chronic infection. While transcriptional evidence of CD40 signaling was seen in
GC B cells undergoing positive selection and GC exit, transcriptional evidence of
BCR signaling was seen only in cells undergoing positive selection. This
suggests that strong T cell help through CD40 signals in the absence of strong
BCR signals may promote GC B cell differentiation and exit during chronic
infection. However, why CD40 agonism did not promote further PC differentiation
during chronic infection is unclear. Whether the lack of response to CD40
pathway modulation in chronic infection was due to suboptimal dosing (Beatty et
al., 2011), impaired antibody Fc-mediated functions during chronic infection
(Wieland et al., 2015), or functional inhibition of this signaling axis warrants
further study. Perhaps more intriguingly, these results suggest that there may be
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an additional signal, like persistent inflammation, that influences how CD40 and
BCR signals are integrated in GC B cells during chronic infection.

4.3 Inflammation: Dominant role of persistent inflammation over
persistent antigen as a driver of B cell dysregulation in chronic
infection
In Chapter 3, we used single cell sequencing at day 15 to determine the
molecular pathways associated with divergence in the terminal PC and MB fates.
As would be predicted by the experiments with CD40 agonism and BCR
inhibition, Transcriptional signatures of CD40 signaling in conjunction with BCR
signaling favored GC B cell DZ reentry whereas CD40 signals in the absence of
BCR signaling favored GC exit in acute infection. In contrast, virus-specific GC B
cell undergoing GC differentiation and GC exit during chronic infection were
enriched and had distinct transcriptional signatures consistent with diminished
CD40 signals, attenuated BCR signaling, and high inflammatory signaling.
Agonism of the CD40 pathway and inhibition of BCR signaling did not impact
virus-specific B cell responses during chronic infection. These results show that
although virus-specific B cell responses to chronic infection did act as predicted
by the BCR-affinity model, with GC B cells favoring differentiation over DZ
reentry, the transcriptional mechanism of this choice is distinct.
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However, a third feature was prominent in the pseudotime analyses of B
cell fate decisions in chronic versus acute infection: inflammatory signaling.
Inflammation during chronic infections is sustained and complex and involves
signals from type I and type II interferons and TNF family members (Stelekati and
Wherry, 2012; Zuniga et al., 2015). Inflammation, particularly type I interferon,
has been shown to promote PC differentiation at the extrafollicular checkpoint
prior to GC B cell differentiation and GC formation yet the impact of inflammation
on GC B cell fate decisions following the formation of the GC was previously
unclear (Fallet et al., 2016; Moseman et al., 2016; Sammicheli et al., 2016). Our
studies in chapter 3 found that type I interferon does impact B cell responses
during chronic viral infection but that the impact of this signaling pathway on B
cell differentiation is likely prior to the formation of the GC consistent with other
studies. Furthermore, development of an experimental system capable of
discriminating the impact of chronic antigen versus persistent inflammation in
vivo identified persistent inflammation rather than chronic antigen exposure as
the mechanism underlying GC B cell skewing during chronic infection.
How attenuated BCR signaling, diminished CD40 signals, and increased
inflammatory signaling leads to PC differentiation during chronic infection is still
unclear. Integration of BCR and Tfh help signals in GC B cells is rewired such
that GC B cells require both signals for positive selection and differentiation (Luo
et al., 2018). As previously discussed, the balance between these two signals is
critical for influencing GC B cell differentiation and DZ re-entry. Importantly,
CD40 signals in GC B cells lead to induction of the canonical NfKB pathway
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which, in addition to activating c-Myc, can promote both PC differentiation and
GC B cell survival (Luo et al., 2018; Milanovic et al., 2017; Roy et al., 2019; De
Silva et al., 2016). While our studies did not identify a single inflammatory
mediator that was causal many inflammatory signaling pathways, like those
downstream of the type I interferon and TNF-a pathways, coalesce on NfKB
activation (Hayden and Ghosh, 2014; Vallabhapurapu and Karin, 2009; Yang et
al., 2001). Aberrant regulation of NfKB can lead to GC disruption (Heise et al.,
2014), PC differentiation, and, in some cases PC malignancies (Annunziata et
al., 2007; Demchenko et al., 2010). Our results are consistent with a model in
which sustained and elevated inflammatory signals drive NfKB activation leading
to PC differentiation and GC exit. Interrogation of the NfKB pathway is an
important future avenue of study. Further, it remains possible that inflammatory
signaling pathways may converge and modify other signaling pathways in GC B
cells like the PI3K-MTOR-Akt pathway possibly leading to altered GC B cell
differentiation (Kaur et al., 2008; Luo et al., 2018, 2019).

4.4 B cell dysfunction in other settings of chronic antigen
exposure – similarities and differences in lessons learned from
chronic LCMV
Chronic LCMV infection is not the only situation in which chronic antigen
exposure has been found to alter B cell responses. HIV and HCV lead to altered
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B cell differentiation (Moir et al., 2008; Racanelli et al., 2006). Humans and mice
infected with malaria-causing parasites also display altered humoral immunity,
specifically altered MB differentiation (Kim et al., 2019; Obeng-Adjei et al., 2017;
Portugal et al., 2015; Thouvenel et al., 2016). Additionally, B cell anergy is a well
described mechanism by which B cell recognizing self-antigen are rendered
functionally inert in an effort to maintain immune tolerance (Yarkoni et al., 2010).
However, the context in which B cells see chronic self-antigen is different when
compared to chronic viral infection indicating that additional cues beyond antigen
loads, like inflammation or periodicity of exposure, are likely critical for regulating
the outcome of the GC response.
It is striking to note the similarity between GC B cells in chronic infection
and B cell anergy in autoimmunity. In the case of autoimmunity, the introduction
of an inflammatory signal, such as infection or type I interferon, can overcome B
cell anergy and lead to robust anti-self antibody responses (Domeier et al.,
2018). Anergic B cells are rendered functionally inert by chronic self-antigen
exposure in a mechanism that involves inhibition of proximal BCR signaling
through upregulation of PTEN and SHIP-1 (both inhibitors of proximal BCR
signaling) (Yarkoni et al., 2010). However, despite the loss of BCR signaling
capacity, anergic B cells are still able to process and present antigen and are
responsive to CD40 signals (Eris et al., 2006). Virus-specific GC B cells in
chronic infection display elevated levels of PDK1 and altered PI3K-Akt signaling,
transcriptional evidence of diminished but present CD40 signal, and
transcriptional signatures consistent with impaired BCR signaling. Whether
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common mechanisms regulate B cell anergy and dysfunctional B cell responses
to chronic infection warrant future study.
It is interesting to consider whether all adaptive immune lineages share a
common transcriptional mechanism that renders them functionally diminished in
settings of chronic antigen exposure and persistent inflammation. CD8 T cell
exhaustion is a well characterized form of T cell dysfunction that occurs during
chronic viral infection (McLane et al., 2019). T cell exhaustion is characterized by
the sequential upregulation of inhibitory receptors that render these cells unable
to undergo full activation and mediate cytotoxicity after undergoing TCR
signaling. Interestingly, many of the same transcription factors and transcriptional
networks seen in exhausted T cells are also seen in virus-specific B cells during
chronic infection. For example, IRF4, which is important for driving PC responses
is also a critical regulator of CD8 T cell fate (Man et al., 2017). Similar to the
BCR-affinity based model of selection, strong TCR signals increase the
intracellular levels of IRF4 which favors the exhaustion fate whereas weak TCR
signals favor the memory fate (Man et al., 2017). Similarly, the Blimp1-Bcl6 axis
which controls PC vs GC B cell fates also influences exhausted T cell fates with
Bcl6+ CD8 T cells representing a more progenitor-like pool (Wu et al., 2016) and
Blimp1+ cells favoring the terminal effector population (Shin et al., 2009). Further
analysis of our scRNAseq and bulk RNAseq data shows a dramatic overlap
between the core T cell exhaustion transcriptional signature and B cells from
chronic infection (unpublished data). This observation suggests that chronic
infection may induce a shared program of immune dysfunction among all
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adaptive immune lineages. Further study will be necessary to define these
shared networks.
Why the adaptive immune system evolved mechanisms to limit T cell
overactivation in the setting of chronic infection is clear as too vigorous a T cell
response could lead to excessive immunopathology and mortality. However, why
chronic infection would promote PC differentiation and delayed affinity maturation
of the humoral immune response is an open question. Does this confer a survival
advantage to the host?

4.5 Impact of these studies on approaches to vaccination
The studies outlined in chapters 2 and 3 of this thesis may have several
important implications for new approaches to vaccination in individuals with preexisting chronic inflammatory conditions. In particular, the finding that
inflammatory signaling plays a dominant role over antigen loads in shaping the
output of the humoral immune response. Chronic inflammation and the resulting
skewing of B cell differentiation may explain why aged individuals or those with
existing chronic infections respond poorly to immunization (McKittrick et al.,
2013; Shive et al., 2018; Wiedmann et al., 2000). Recently, it has been
demonstrated that repeated antigen exposure, in the context of rational vaccine
design for HIV, can greatly augment GC responses leading to increased affinity
maturation and the production of broadly neutralizing antibodies (Cirelli et al.,
2019; Tam et al., 2016). Our studies support this approach and further suggest
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that the choice of adjuvants that induce low but not high levels of inflammation
will be important for optimally guiding affinity maturation of the GC response and
balancing the output of the GC response.
Importantly, the work contained within this thesis extends our knowledge
of the mechanisms underlying GC B cell positive selection and GC exit and
therapeutic manipulation of the mechanisms described could allow finer control
over the output of the humoral immune response. While the accumulation of
affinity-increasing mutations is an important goal for vaccine responses to HIV
(Briney et al., 2016; Doria-Rose and Joyce, 2015; Kwong and Mascola, 2018),
the optimal humoral immune response for other pathogens may be different. For
example, seasonal re-exposure to influenza infection or vaccination leads to
repeated recruitment of MB cells into the recall response (Linderman and
Hensley, 2016; Zost et al., 2019). One impact of this is that individuals have
focusing of antibody responses towards epitopes the immune system has
already seen. However, due to genetic alterations in the influenza viral proteins
neuraminidase and hemagglutinin from year to year, a process known as
antigenic drift, epitopes in these proteins that mediate neutralization can change
and antibody responses that were previously effective can be rendered
ineffective (Cobey and Hensley, 2017; Wilson et al., 2013b). Therefore, for
vaccine responses against influenza, it may be desired to generate more diverse
antibody responses against a variety of epitopes rather than high-affinity
responses against one or a few epitopes. While our studies have focused on
humoral immune responses that necessitate high-affinity antibodies to mediate
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viral control, it is likely that by using similar approaches to track and
transcriptionally profile virus-specific B cell responses in other mouse models will
yield further mechanistic insights relevant to vaccine design.

4.6: Adding a fourth dimension - Spatial dysregulation at the
tissue level during chronic infection is a big black box and may
underly many aspects of adaptive immune dysfunction during
chronic infection
One important and often overlooked aspect of many studies in
immunology is the role that immune cell spatial location within tissues plays in
regulating the immune response. While the studies completed in chapters 2 and
3 of this thesis provide increased mechanistic understanding of the GC B cell
response during viral infection and identify a key GC B cell checkpoint that is
dysregulated during chronic viral infection, our studies involved processing of
tissues and loss of spatial information. The importance of GC structure is
perhaps best illustrated by mice with lack the FOXO1 transcription factor in the B
cell lineage. Loss of FOXO1 results in disorganization of the DZ GC B cell
program and loss of GC polarization (Dominguez-Sola et al., 2015; Inoue et al.,
2017). GC disorganization in the setting of FOXO1 deficiency results in impaired
affinity maturation (Dominguez-Sola et al., 2015). GC B cell movement between
the LZ and DZ is critical as GC B cells without CXCR4 are unable to migrate to
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the DZ efficiently and display impaired affinity maturation relative to CXCR4sufficient GC B cells (Allen et al., 2004).
Many infections cause alterations to tissue homeostasis and tissue
architecture that are resolved upon pathogen clearance. In contrast to acute
infections, chronic infections can lead to immunopathology and disruption of
tissue architecture. In HIV, disruption of the gut barrier can lead to bacterial
translocation and inflammation (Brenchley et al., 2006; Klatt et al., 2013; Nazli et
al., 2010). Chronic LCMV infection leads to disruption of splenic architecture as
macrophages and stromal cells, like FDC, are infected and eliminated by the
cytotoxic T cell response (Matter et al., 2011; Mueller et al., 2007; Wilson et al.,
2013a). Given the central role that FDC play in regulating the GC response (Allen
and Cyster, 2008; Cyster and Allen, 2019; Heesters et al., 2014), it is likely that
disruption of the splenic architecture does play a role in modulating virus-specific
GC B cell responses. Indeed, blockade of type I interferon can prevent splenic
architecture disruption and leads to induction of the GC program in virus-specific
B cells during chronic infection (Wilson et al., 2013a). While the studies in this
thesis mainly focused on phenotypic and transcriptomic characterization of virusspecific B cell responses during chronic infection, we did analyze the histological
appearance of GCs. We found that histological evidence of GCs was present
during acute and chronic infection and that GC size was the same regardless of
infection. However, while GCs were the same size, the shape of GCs during
chronic infection were distinct, displaying less circularity. Whether altered GC
shape contributes to impaired affinity maturation and skewed GC B cell
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differentiation during chronic infection remains unclear and will require further
study.
It should be noted that we observed phenotypic and transcriptional
polarization of GC B cells into the LZ and DZ compartments in both acute and
chronic infection. Whether these observations translate into distinct spatial
localization of these cells is an important future question. It will be especially
interesting to see whether the clusters identified in our scRNAseq analysis of the
GC B cell response translate into unique spatial localization of these clusters.
However, one limitation to conducting these studies this is the current technical
limitations of immunofluorescent microscopy. Traditional microscopy approaches
have been limited to simultaneous analysis of at best 6 markers. Recent
technical advances in our ability to assess a higher number of markers
simultaneously using microscopy may advance our understanding of how spatial
localization informs GC responses. Techniques such as co-detecting by indexing
(CODEX) (Goltsev et al., 2018) or multiplexed ion beam imaging (MIBI) (Angelo
et al., 2014) allow the detection of 50+ markers on the same tissue sample. More
widespread adoption of these technologies could allow finer dissection of the GC
response and allow identification and validation of not only our scRNAseq data
but other researcher’s scRNAseq findings. One particularly interesting possibility
is the use of these techniques to understand how acute infection versus chronic
infection perturbs tissue-level homeostasis and what the return to homeostasis
looks like in these two settings.
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4.7 Concluding thoughts
The work presented in this thesis provides novel insight into the molecular
control of B cell responses to chronic viral infections. Prior to this work, it was
unclear whether or how chronic viral infection impacted GC B cell responses and
more specifically how chronic antigen and inflammation impact GC B cell
differentiation. To address these questions, we interrogated the impact of chronic
viral infection on B cell differentiation and fate decisions within the GC. Focusing
specifically on virus-specific B cells, we employed a combination of bulk and
single cell RNA sequencing (scRNA-seq), together with BCR repertoire profiling
and in vivo cellular experiments. The studies in chapters 2 and 3 of this thesis
revealed a key GC checkpoint dysregulated during chronic infection. Specifically,
during chronic viral infection, GC B cells inefficiently re-enter the dark zone
during the cyclic GC reaction and instead GC B cell fate is skewed towards
premature exit as MB or terminal PC. This short-circuiting of the cyclic process of
GC B cell development occurred at a key light zone step in GC B cell
differentiation and was associated with decreased affinity maturation and serum
antibody avidity. Single cell profiling pointed to attenuated BCR signaling and
CD40 signaling, but amplified inflammatory signals associated with this altered
GC developmental pattern. Manipulation of the CD40 pathway, antigen
chronicity, and inflammation identified a dominant role for inflammation in
promoting skewed GC B cell differentiation during chronic infection. Our studies
reveal the mechanistic roles of inflammation, CD40 signaling and antigen loads
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on B cell differentiation during chronic viral infection and identify key pathways
that can be targeted to modulate humoral immune responses and promote
affinity maturation during anti-viral immune responses and immunization.
Additionally, these observations have important implications for generating
optimal antibody responses during chronic infections.
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